<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults - Simon, ST - 2016 | Cochrane Library</title> <meta content="Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults - Simon, ST - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007354.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults - Simon, ST - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007354.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007354.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults" name="citation_title"/> <meta content="Steffen T Simon" name="citation_author"/> <meta content="steffen@steffensimon.de" name="citation_author_email"/> <meta content="Irene J Higginson" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Sara Booth" name="citation_author"/> <meta content="Cambridge University Hospitals" name="citation_author_institution"/> <meta content="Richard Harding" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Vera Weingärtner" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Claudia Bausewein" name="citation_author"/> <meta content="LMU Munich" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD007354.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/10/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007354.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007354.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007354.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Benzodiazepines [adverse effects, *therapeutic use]; Dyspnea [*drug therapy, etiology]; Lung Neoplasms [*complications]; Pulmonary Disease, Chronic Obstructive [*complications]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007354.pub3&amp;doi=10.1002/14651858.CD007354.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007354\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007354\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007354.pub3",title:"Benzodiazepines for the relief of breathlessness in advanced malignant and non\\u2010malignant diseases in adults",firstPublishedDate:"Oct 20, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007354.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007354.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007354.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007354.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007354.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007354.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007354.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007354.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007354.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007354.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8440 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007354.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-sec-0090"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/appendices#CD007354-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/table_n/CD007354StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/table_n/CD007354StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information#CD007354-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Steffen T Simon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information#CD007354-cr-0003">Irene J Higginson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information#CD007354-cr-0004">Sara Booth</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information#CD007354-cr-0005">Richard Harding</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information#CD007354-cr-0006">Vera Weingärtner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information#CD007354-cr-0007">Claudia Bausewein</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information/en#CD007354-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 October 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007354.pub3">https://doi.org/10.1002/14651858.CD007354.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007354-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007354-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007354-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007354-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007354-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007354-abs-0001" lang="en"> <section id="CD007354-sec-0001"> <h3 class="title" id="CD007354-sec-0001">Background</h3> <p>This is an updated version of the original Cochrane review published in Issue 1, 2010, on 'Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults'. Breathlessness is one of the most common symptoms experienced in the advanced stages of malignant and non‐malignant disease. Benzodiazepines are widely used for the relief of breathlessness in advanced diseases and are regularly recommended in the literature. At the time of the previously published Cochrane review, there was no evidence for a beneficial effect of benzodiazepines for the relief of breathlessness in people with advanced cancer and chronic obstructive pulmonary disease (COPD). </p> </section> <section id="CD007354-sec-0002"> <h3 class="title" id="CD007354-sec-0002">Objectives</h3> <p>The primary objective of this review was to determine the efficacy of benzodiazepines for the relief of breathlessness in people with advanced disease. Secondary objectives were to determine the efficacy of different benzodiazepines, different doses of benzodiazepines, different routes of application, adverse effects of benzodiazepines, and the efficacy in different disease groups. </p> </section> <section id="CD007354-sec-0003"> <h3 class="title" id="CD007354-sec-0003">Search methods</h3> <p>This is an update of a review published in 2010. We searched 14 electronic databases up to September 2009 for the original review. We checked the reference lists of all relevant studies, key textbooks, reviews, and websites. For the update, we searched CENTRAL, MEDLINE, and EMBASE and registers of clinical trials for further ongoing or unpublished studies, up to August 2016. We contacted study investigators and experts in the field of palliative care asking for further studies, unpublished data, or study details when necessary. </p> </section> <section id="CD007354-sec-0004"> <h3 class="title" id="CD007354-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and controlled clinical trials (CCTs) assessing the effect of benzodiazepines compared with placebo or active control in relieving breathlessness in people with advanced stages of cancer, chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), motor neurone disease (MND), and idiopathic pulmonary fibrosis (IPF). </p> </section> <section id="CD007354-sec-0005"> <h3 class="title" id="CD007354-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed identified titles and abstracts. Three review authors independently performed assessment of all potentially relevant studies (full text), data extraction, and assessment of methodological quality. We carried out meta‐analysis where appropriate. </p> </section> <section id="CD007354-sec-0006"> <h3 class="title" id="CD007354-sec-0006">Main results</h3> <p>Overall, we identified eight studies for inclusion: seven in the previous review and an additional study for this update. We also identified two studies awaiting classification in this update. The studies were small (a maximum number of 101 participants) and comprised data from a total of 214 participants with advanced cancer or COPD, which we analysed. There was only one study of low risk of bias. Most of the studies had an unclear risk of bias due to lack of information on random sequence generation, concealment, and attrition. Analysis of all studies did not show a beneficial effect of benzodiazepines for the relief of breathlessness (the primary outcome) in people with advanced cancer and COPD (8 studies, 214 participants) compared to placebo, midazolam, morphine, or promethazine. Furthermore, we observed no statistically significant effect in the prevention of episodic breathlessness (breakthrough dyspnoea) in people with cancer (after 48 hours: risk ratio of 0.76 (95% CI 0.53 to 1.09; 2 studies, 108 participants)) compared to morphine. Sensitivity analyses demonstrated no statistically significant differences regarding type of benzodiazepine, dose, route and frequency of delivery, duration of treatment, or type of control. Benzodiazepines caused statistically significantly more adverse events, particularly drowsiness and somnolence, when compared to placebo (risk difference 0.74 (95% CI 0.37, 1.11); 3 studies, 38 participants). In contrast, two studies reported that morphine caused more adverse events than midazolam (RD ‐0.18 (95% CI ‐0.31, ‐0.04); 194 participants). </p> </section> <section id="CD007354-sec-0007"> <h3 class="title" id="CD007354-sec-0007">Authors' conclusions</h3> <p>Since the last version of this review, we have identified one new study for inclusion, but the conclusions remain unchanged. There is no evidence for or against benzodiazepines for the relief of breathlessness in people with advanced cancer and COPD. Benzodiazepines caused more drowsiness as an adverse effect compared to placebo, but less compared to morphine. Benzodiazepines may be considered as a second‐ or third‐line treatment, when opioids and non‐pharmacological measures have failed to control breathlessness. There is a need for well‐conducted and adequately powered studies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007354-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007354-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007354-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007354-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007354-abs-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007354-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007354-abs-0002" lang="en"> <h3>Benzodiazepines for the relief of breathlessness in advanced diseases in adults</h3> <p><b>Background</b> </p> <p>Breathlessness is a common and distressing symptom in advanced cancer and other diseases at the end of life. Treating breathlessness sufficiently remains very difficult. Benzodiazepines are a group of sedating medicines (drugs), including lorazepam, clorazepate, diazepam, alprazolam, and temazepam, that are used mainly for sleep disturbance and anxiety, but are widely used for the relief of breathlessness. </p> <p><b>Key results</b> </p> <p>In this updated systematic review we aimed to determine whether benzodiazepines relieved breathlessness in adults with advanced disease. In August 2016, we found eight studies. </p> <p>Benzodiazepines caused more side effects such as drowsiness or somnolence when compared to placebo but caused less side effects when compared to morphine. Our review therefore supports the use of benzodiazepines only if other first‐line treatments, such as opioids and non‐drug treatments, have failed. However, there is still an urgent need for more studies in this field to find better ways to relieve this burdensome symptom in people with advanced diseases. </p> <p>We concluded in summary that there is no evidence that benzodiazepines relieve breathlessness in adults with advanced disease. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007354-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007354-sec-0096"></div> <h3 class="title" id="CD007354-sec-0097">Implications for practice</h3> <section id="CD007354-sec-0097"> <p>For the update of this review, we identified one additional study for inclusion, but the conclusions remain unchanged. </p> <p> <ul id="CD007354-list-0019"> <li> <p>There is no evidence for a beneficial effect of benzodiazepines in the relief of breathlessness in people with advanced cancer and COPD. There is a non‐significant beneficial effect, but the overall effect size is small. Benzodiazepines caused more drowsiness as an adverse effect compared to placebo but less compared to morphine. These results justify considering benzodiazepines as second‐ or third‐line treatment, when opioids and non‐pharmacological measures have failed to control breathlessness. Although we included a few low‐ to high‐quality studies in this review, there is still a further need for well‐conducted and adequately powered studies in this field. </p> </li> <li> <p>There is currently not enough evidence to support the use of benzodiazepines in the prevention of episodic breathlessness in people with cancer. There are no data from controlled trials for the treatment of episodic breathlessness with benzodiazepines. </p> </li> <li> <p>There are no differences regarding the type of benzodiazepine, dose, mode and frequency of administration, and duration of treatment. </p> </li> </ul> </p> </section> <h3 class="title" id="CD007354-sec-0098">Implications for research</h3> <section id="CD007354-sec-0098"> <p>Although we included a few high‐quality studies in this review, there is still a further need for more well‐conducted and larger studies in this field. Further research should pay attention to the following issues. </p> <p> <ul id="CD007354-list-0020"> <li> <p>Larger studies with more participants to reach a statistically sound conclusion are required. </p> </li> <li> <p>More attention should be paid to the reporting of methodological details of randomised controlled trials because this is essential for interpretation of the results. </p> </li> <li> <p>Studies in chronic heart failure (CHF), motor neurone disease (MND), idiopathic pulmonary fibrosis (IPF), and other life‐threatening diseases with breathlessness (e.g. advanced renal failure) are needed. </p> </li> <li> <p>Treatment of episodic breathlessness with benzodiazepines has not yet been studied in controlled trials. </p> </li> <li> <p>Benzodiazepines in the relief of breathlessness with panic attacks might be worth studying. </p> </li> </ul> </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007354-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007354-sec-0022"></div> <p>This review is an update of a previously published review in the Cochrane Database of Systematic Reviews, Issue 1, 2010, on 'Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults'<i>.</i> </p> <section id="CD007354-sec-0023"> <h3 class="title" id="CD007354-sec-0023">Description of the condition</h3> <p>The American Thoracic Society defines breathlessness as "a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity. The experience derives from interactions among multiple physiological, psychological, social, and environmental factors, and may induce secondary physiological and behavioral responses" (<a href="./references#CD007354-bbs2-0129" title="ParshallMB , SchwartzsteinRM , AdamsL , BanzettRB , ManningHL , BourbeauJ , et al. An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea. American Journal of Respiratory and Critical Care Medicine2012;185(4):435‐52. ">Parshall 2012</a>). This multidimensional concept of breathlessness as 'total breathlessness' is comparable with the concepts of 'total pain' or 'total suffering' (<a href="./references#CD007354-bbs2-0105" title="BoothS , DudgeonD , editors. Dyspnoea in Advanced Disease ‐ a Guide to Clinical Management. 1st Edition. Oxford: Oxford University Press, 2006. ">Booth 2006</a>). The term 'breathlessness' is used interchangeably with dyspnoea, shortness of breath, breathing difficulty, and laboured breathing. Breathlessness is defined as refractory when it persists despite optimal treatment of the underlying condition (<a href="./references#CD007354-bbs2-0113" title="DormanS , JolleyC , AbernethyA , CurrowD , JohnsonM , FarquharM , et al. Researching breathlessness in palliative care: consensus statement of the National Cancer Research Institute Palliative Care Breathlessness Subgroup. Palliative Medicine2009;23(3):213‐27. ">Dorman 2009</a>), and can manifest as continuous breathlessness or episodic breathlessness (<a href="./references#CD007354-bbs2-0135" title="SimonST , HigginsonIJ , BenaliaH , GyselsM , MurtaghFE , SpicerJ , et al. Episodic and continuous breathlessness: a new categorization of breathlessness. Journal of Pain and Symptom Management2012;45(6):1019‐29. ">Simon 2012</a>; <a href="./references#CD007354-bbs2-0136" title="SimonST , WeingärtnerV , HigginsonIJ , VoltzR , BauseweinC . Definition, categorization, and terminology of episodic breathlessness: consensus by an International Delphi Survey. Journal of Pain and Symptom Management2014;47(5):828‐38. ">Simon 2014</a>). </p> <p>Breathlessness is one of the most common symptoms in the last year of life (<a href="./references#CD007354-bbs2-0121" title="HigginsonIJ , Addington‐HallJ . The epidemiology of death and symptoms. In: DoyleD , HanksG , ChernyN , CalmanK editor(s). Oxford Textbook of Palliative Medicine. 3rd Edition. Oxford: Oxford University Press, 2004:14‐24. ">Higginson 2004</a>). In advanced diseases, it is highly prevalent in chronic obstructive pulmonary disease (COPD) (56% to 98%), chronic heart failure (CHF) (18% to 88%), and cancer (16% to 77%) (<a href="./references#CD007354-bbs2-0126" title="MoensK , HigginsonIJ , HardingR . Are there differences in the prevalence of palliative care‐related problems in people living with advanced cancer and eight non‐cancer conditions? A systematic review. Journal of Pain and Symptom Management2014; Vol. 48, issue 4:660‐77. [PUBMED: 24801658] ">Moens 2014</a>). It is a distressing symptom for the patient, but also for the caregivers (<a href="./references#CD007354-bbs2-0128" title="NordgrenL , SorensenS . Symptoms experienced in the last six months of life in patients with end‐stage heart failure. European Journal of Cardiovascular Nursing2003;2:213‐7. ">Nordgren 2003</a>). The frequency and severity of breathlessness increases during the course of the disease until death (<a href="./references#CD007354-bbs2-0109" title="CurrowDC , SmithJ , DavidsonPM , NewtonPJ , AgarMR , AbernethyAP . Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. Journal of Pain and Symptom Management2010;39(4):680‐90. ">Currow 2010</a>; <a href="./references#CD007354-bbs2-0134" title="SeowH , BarberaL , SutradharR , HowellD , DudgeonD , AtzemaC , et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology2011;29(9):1151‐8. ">Seow 2011</a>). Furthermore, breathlessness may be related to anxiety and depression (<a href="./references#CD007354-bbs2-0127" title="NeumanA , GunnbjornsdottirM , TunsaterA , NystromL , FranklinKA , NorrmanE , et al. Dyspnea in relation to symptoms of anxiety and depression: a prospective population study. Respiratory Medicine2006;100:1843‐9. ">Neuman 2006</a>), thus treatment of anxiety and depression may reduce this symptom. However, the contribution, the causal relationship, and the direction of influence are still unclear (<a href="./references#CD007354-bbs2-0106" title="BoothS , MoosaviSH , HigginsonIJ . The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy. Nature Clinical Practice Oncology2008;5:90‐100. ">Booth 2008</a>). </p> <p>Different diseases cause breathlessness, such as primary and secondary cancer, COPD, CHF, motor neurone disease (MND), and cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis (IPF). The advanced stage of each disease must be defined separately because of the different disease trajectories. The pathophysiology of breathlessness depends mainly on the underlying cause. It includes, for example, airway obstruction, reduction of lung or gas exchange capacity, muscle weakness, degeneration of neurons, or reduction of blood diffusing capacity. The pathological pathway is complex and beyond a sole reduction of PO<sub>2</sub> (partial pressure of oxygen) or increase of PCO<sub>2</sub> (partial pressure of carbon dioxide) (<a href="./references#CD007354-bbs2-0124" title="ManningHL , SchwartzsteinRM . Pathophysiology of dyspnea. The New England Journal of Medicine1995;333:1547‐53. ">Manning 1995</a>). The medulla in the brain stem, the motor and sensory cortex, peripheral and central chemoreceptors, and mechanoreceptors in the airways and chest wall are the main sites of action responsible for the perception of breathlessness (<a href="./references#CD007354-bbs2-0106" title="BoothS , MoosaviSH , HigginsonIJ . The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy. Nature Clinical Practice Oncology2008;5:90‐100. ">Booth 2008</a>). There are different explanations of how different parts interact and induce the sensation of breathlessness, such as corollary discharge, afferent‐reafferent dissociation, and receptor reaction. The corollary discharge describes the hypothesis that a sensory 'copy' of the motor output is sent from the motor cortex to the sensory cortex and imparts a conscious awareness of respiratory effort, and is the most widely accepted hypothesis (<a href="./references#CD007354-bbs2-0104" title="BeachD , SchwartzsteinRM . The genesis of breathlessness ‐ what do we understand?. In: BoothS , DudgeonD editor(s). Dyspnoea in Advanced Disease ‐ a Guide to Clinical Management. 1st Edition. Oxford: Oxford University Press, 2006:1‐18. ">Beach 2006</a>). </p> <p>After treatment of the underlying cause, symptom management of breathlessness includes non‐pharmacological and pharmacological interventions. A recent Cochrane Review on non‐pharmacological interventions for the relief of breathlessness in advanced disease showed effectiveness of neuro‐electrical muscle stimulation, chest wall vibration, walking aids, and breathing training (<a href="./references#CD007354-bbs2-0103" title="BauseweinC , BoothS , GyselsM , HigginsonIJ . Non‐pharmacological interventions for breathlessness in advanced stages of malignant and non‐malignant diseases. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005623.pub2] ">Bausewein 2008</a>). A recent review on the use of oxygen highlights that there is a statistically and clinically significant benefit for both ambulatory and long‐term oxygen in COPD, but no consistent evidence for their use in cancer (<a href="./references#CD007354-bbs2-0108" title="CranstonJM , CrockettA , CurrowD . Oxygen therapy for dyspnoea in adults. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD004769.pub2] ">Cranston 2008</a>). </p> <p>Opioids are the first choice in the pharmacological management of refractory breathlessness. A Cochrane Review showed evidence for the use of oral and parenteral application of opioids, but there is currently no evidence for nebulised opioids (<a href="./references#CD007354-bbs2-0122" title="JenningsAL , DaviesAN , HigginsJP , BroadleyK . Opioids for the palliation of breathlessness in terminal illness. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD002066] ">Jennings 2001</a>; <a href="./references#CD007354-bbs2-0129" title="ParshallMB , SchwartzsteinRM , AdamsL , BanzettRB , ManningHL , BourbeauJ , et al. An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea. American Journal of Respiratory and Critical Care Medicine2012;185(4):435‐52. ">Parshall 2012</a>). However, most of the studies were underpowered, and there is a need for further well‐designed studies to investigate the effectiveness in different diseases, applications, and doses. Besides opioids, there are other drugs for the palliation of breathlessness, such as steroids (for lymphangitis carcinomatosa), inhaled local anaesthetics, or more sedating drugs such as benzodiazepines, phenothiazines, buspirone, or chlorpromazine, with variable evidence in symptom control (<a href="./references#CD007354-bbs2-0111" title="DavisC . Drug therapies. In: AhmedzaiSH , MuersMF editor(s). Supportive Care in Respiratory Disease. 1st Edition. Oxford: Oxford University Press, 2005:147‐63. ">Davis 2005</a>; <a href="./references#CD007354-bbs2-0129" title="ParshallMB , SchwartzsteinRM , AdamsL , BanzettRB , ManningHL , BourbeauJ , et al. An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea. American Journal of Respiratory and Critical Care Medicine2012;185(4):435‐52. ">Parshall 2012</a>). </p> </section> <section id="CD007354-sec-0024"> <h3 class="title" id="CD007354-sec-0024">Description of the intervention</h3> <p>Benzodiazepines are frequently used in the management of breathlessness in advanced diseases and are regularly recommended in textbooks for palliative medicine or clinical guidelines (<a href="./references#CD007354-bbs2-0105" title="BoothS , DudgeonD , editors. Dyspnoea in Advanced Disease ‐ a Guide to Clinical Management. 1st Edition. Oxford: Oxford University Press, 2006. ">Booth 2006</a>; <a href="./references#CD007354-bbs2-0107" title="BrueraE , HigginsonIJ , RobbSD , vonGuntenCF . Textbook of Palliative Medicine. 1st Edition. London: Hodder Arnold, 2006. ">Bruera 2006</a>). The most common drugs are diazepam, midazolam, alprazolam, and lorazepam. However, there are more than 40 different benzodiazepines (<a href="./references#CD007354-bbs2-0119" title="HardmanJG , LimbirdLE . Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 11th Edition. New York: McGraw‐Hill, 2005. ">Hardman 2005</a>). </p> </section> <section id="CD007354-sec-0025"> <h3 class="title" id="CD007354-sec-0025">How the intervention might work</h3> <p>It is increasingly evident that breathlessness interacts with mental health, for example anxiety and depression and anxiety or panic can trigger or worsen breathlessness (<a href="./references#CD007354-bbs2-0106" title="BoothS , MoosaviSH , HigginsonIJ . The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy. Nature Clinical Practice Oncology2008;5:90‐100. ">Booth 2008</a>; <a href="./references#CD007354-bbs2-0110" title="DavisCL . ABC of palliative care. BMJ1997;315(7113):931‐4. ">Davis 1997</a>). Benzodiazepines are anxiolytics, which have sedating effects and are intended to relieve anxiety and might therefore have palliating effects for breathlessness. </p> <p>Benzodiazepines belong to the group of hypnotics and sedatives. Their core chemical structure is a fusion of the benzene and the diazepine ring with various modifications that are responsible for the different compounds of the drug. The interaction of benzodiazepines with specific subunits of GABA (gamma‐aminobutyric acid) receptors is responsible for their mechanism of action. The central and main effects of benzodiazepines are sedative‐hypnotic, muscle‐relaxant, anxiolytic, and anticonvulsant. Side effects include impairment of mental and motor function, light‐headedness, and nausea (<a href="./references#CD007354-bbs2-0119" title="HardmanJG , LimbirdLE . Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 11th Edition. New York: McGraw‐Hill, 2005. ">Hardman 2005</a>). Physical dependence is a huge problem in long‐term use of benzodiazepines. There is no effect on respiration (for example depression of respiration) in normal doses, and only a slight depression of ventilation in higher doses (<a href="./references#CD007354-bbs2-0119" title="HardmanJG , LimbirdLE . Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 11th Edition. New York: McGraw‐Hill, 2005. ">Hardman 2005</a>). The main therapeutic uses are insomnia, anxiety disorders, acute epilepsy, alcohol withdrawal, and anaesthetic premedication (<a href="./references#CD007354-bbs2-0119" title="HardmanJG , LimbirdLE . Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 11th Edition. New York: McGraw‐Hill, 2005. ">Hardman 2005</a>). The group of non‐benzodiazepines (for example zolpidem) act on the same receptors with similar effects, but have a different chemical structure. We have not included these in this review as they do not belong to the benzodiazepine group. </p> </section> <section id="CD007354-sec-0026"> <h3 class="title" id="CD007354-sec-0026">Why it is important to do this review</h3> <p>Despite the frequent use of benzodiazepines for the relief of breathlessness in palliative care, the evidence for their efficacy is still unclear. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007354-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007354-sec-0027"></div> <p>The primary objective of this review was to determine the efficacy of benzodiazepines for the relief of breathlessness in people with advanced disease. </p> <p>Secondary objectives were to determine the efficacy of different benzodiazepines, different doses of benzodiazepines, different routes of application, adverse effects of benzodiazepines, and the efficacy in different disease groups. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007354-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007354-sec-0028"></div> <section id="CD007354-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007354-sec-0030"> <h4 class="title">Types of studies</h4> <p> <ul id="CD007354-list-0001"> <li> <p>Randomised controlled trials (RCTs). We defined 'randomised' as studies described by the authors as 'randomised' anywhere in the manuscript. </p> </li> <li> <p>Controlled clinical trials (CCTs).</p> </li> </ul> </p> <p>While writing the protocol, we expected a limited number of studies and therefore decided also to include controlled trials, giving special consideration to the higher risk of bias in these trials in the analysis. </p> </section> <section id="CD007354-sec-0031"> <h4 class="title">Types of participants</h4> <p>Adult participants described as suffering from either breathlessness, dyspnoea, shortness of breath, difficult breathing, or laboured breathing due to advanced malignant and non‐malignant diseases. </p> <p>The advanced stages of diseases included the following.</p> <p> <ul id="CD007354-list-0002"> <li> <p>Cancer: advanced local or metastatic disease.</p> </li> <li> <p>COPD: stage III (severe) or IV (very severe) according to the Global Initiative for Obstructive Lung Disease (GOLD) classification. This includes people with airflow limitation of FEV1 &lt; 50%, FEV1/FVC &lt; 0.7 (FEV1: forced expiratory volume in one second; FVC: forced vital capacity) and symptoms such as more severe breathlessness, reduced exercise capacity, and repeated exacerbations (<a href="./references#CD007354-bbs2-0118" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD (2007). http://www.goldcopd.org (accessed 31 January 2008). ">GOLD 2007</a>). </p> </li> <li> <p>CHF: stage III or IV of the New York Heart Association (NYHA) classification including symptoms such as breathlessness or palpitation and an increasing limitation of exercise capacity and discomfort at rest. </p> </li> <li> <p>MND: all participants suffering from breathlessness.</p> </li> <li> <p>IPF: all participants suffering from breathlessness as the most prominent and disabling symptom. </p> </li> </ul> </p> <p>We excluded studies including participants with acute or chronic asthma, pneumonia, or other potentially curable diseases. Participants included in the studies could be in any care setting (for example hospital or home care). </p> <p>We included studies evaluating participants on oxygen as long as oxygen was used in both the intervention and the control arm. </p> </section> <section id="CD007354-sec-0032"> <h4 class="title">Types of interventions</h4> <p>The use of benzodiazepines (at any dose, any frequency (also single dose), any duration, and through any route) for the relief of breathlessness compared with placebo or active control. We included all drugs that belong to the pharmacological group of benzodiazepines (<a href="./references#CD007354-bbs2-0119" title="HardmanJG , LimbirdLE . Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 11th Edition. New York: McGraw‐Hill, 2005. ">Hardman 2005</a>). </p> </section> <section id="CD007354-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD007354-sec-0034"> <h5 class="title">Primary outcomes</h5> <p>Primary outcomes included subjective measurements of breathlessness on validated and reliable scales such as: </p> <p> <ul id="CD007354-list-0003"> <li> <p>uni‐dimensional scales (e.g. visual analogue scales (VAS), numeric rating scales (NRS), categorical scales, modified Borg scales); or </p> </li> <li> <p>multidimensional scales (e.g. St. George's Respiratory Questionnaire (SGRQ), Chronic Respiratory Disease Questionnaire (CRQ)). </p> </li> </ul> </p> <p>We included studies that measured breathlessness as a primary or secondary outcome, and also studies evaluating breathlessness at rest or on exercise. </p> </section> <section id="CD007354-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes included:</p> <p> <ol id="CD007354-list-0004"> <li> <p>measurement of anxiety;</p> </li> <li> <p>measurement of depression;</p> </li> <li> <p>adverse effects of benzodiazepines;</p> </li> <li> <p>functional exercise capacity (e.g. walking tests);</p> </li> <li> <p>measurement of quality of life; and</p> </li> <li> <p>attrition.</p> </li> </ol> </p> </section> </section> </section> <section id="CD007354-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <p>We ran the search for the original review on 12 September 2009 and ran a subsequent search on 23 August 2016. </p> <section id="CD007354-sec-0037"> <h4 class="title">Electronic searches</h4> <p>For the original review, we identified studies from a search of the following 14 databases:</p> <p> <ul id="CD007354-list-0005"> <li> <p>the Cochrane Pain, Palliative and Supportive Care Trials Register (12 September 2009);</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2009, Issue 3) (12 September 2009); </p> </li> <li> <p>the Cochrane Database of Systematic Reviews (CDSR) in the Cochrane Library (12 September 2009); </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE) (12 September 2009);</p> </li> <li> <p>MEDLINE (1950 to 12 September 2009);</p> </li> <li> <p>EMBASE (1980 to 12 September 2009);</p> </li> <li> <p>CINAHL (1980 to 12 September 2009);</p> </li> <li> <p>PsycINFO (1806 to 12 September 2009);</p> </li> <li> <p>American College of Physicians (ACP) Journal Club (12 September 2009);</p> </li> <li> <p>Health Technology Assessment (HTA) Database (12 September 2009);</p> </li> <li> <p>NHS Economic Evaluation Database (NHSEED) (12 September 2009);</p> </li> <li> <p>Database of Halley Stewart Library (St. Christopher's Hospice) (12 September 2009);</p> </li> <li> <p>International Pharmaceutical Abstracts (1970 to 12 September 2009); and</p> </li> <li> <p>Iowa Drug Information System (IDIS) (1966 to 12 September 2009).</p> </li> </ul> </p> <p>For the update, we searched:</p> <p> <ul id="CD007354-list-0006"> <li> <p>CENTRAL Issue 7 2016 (the Cochrane Library) (searched 2009 to 2016);</p> </li> <li> <p>MEDLINE &amp; Medline in Process (OVID) (Sept 2009 to 23 August 2016);</p> </li> <li> <p>EMBASE (OVID) (September 2009 to 23 August 2016).</p> </li> </ul> </p> <p>We decided not to search the other databases searched for the original review as they did not yield any useful records. </p> <p>We searched the following study registers or meta registers of clinical trials for ongoing or unpublished studies for the update: </p> <p> <ul id="CD007354-list-0007"> <li> <p>ClinicalTrials.gov (08 July 2016);</p> </li> <li> <p>metaRegister of Controlled trials (mRCT) ‐ active registers (08 July 2016);</p> </li> <li> <p>WHO International Clinical Trials Registry Platform (08 July 2016).</p> </li> </ul> </p> <p>We again contacted study investigators and experts in the field of palliative care to ask for further studies, unpublished data, or study details when necessary. </p> <p>Please see <a href="./appendices#CD007354-sec-0102">Appendix 1</a> for the search strategies applied in the original review. <a href="./appendices#CD007354-sec-0103">Appendix 2</a> shows the search strategies applied in this update, with minor changes in lines 3 and 5 (in line 3 to ensure that both British and US spellings of labour/labor were picked up; in line 5 to ensure that both of the phrases 'shortness of breath' and 'short of breath' were included). </p> </section> <section id="CD007354-sec-0038"> <h4 class="title">Searching other resources</h4> <section id="CD007354-sec-0039"> <h5 class="title">Handsearching</h5> <p>We checked the reference lists of all relevant studies, key textbooks, and key websites for further relevant studies. We checked the reference lists of several reviews on the subject (<a href="./references#CD007354-bbs2-0101" title="AbernethyAP , UronisHE , WheelerJL , CurrowDC . Pharmacological management of breathlessness in advanced disease. Progress in Palliative Care2008;16(1):15‐20. ">Abernethy 2008</a>; <a href="./references#CD007354-bbs2-0010" title="AllenSC . Treatment of dyspnoea: the role of drugs. Drugs of Today1984;8:397‐403. ">Allen 1984</a>; <a href="./references#CD007354-bbs2-0102" title="AltoseMD . Assessment and management of breathlessness. Chest1985;88:77S‐83S. ">Altose 1985</a>; <a href="./references#CD007354-bbs2-0103" title="BauseweinC , BoothS , GyselsM , HigginsonIJ . Non‐pharmacological interventions for breathlessness in advanced stages of malignant and non‐malignant diseases. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005623.pub2] ">Bausewein 2008</a>; <a href="./references#CD007354-bbs2-0106" title="BoothS , MoosaviSH , HigginsonIJ . The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy. Nature Clinical Practice Oncology2008;5:90‐100. ">Booth 2008</a>; <a href="./references#CD007354-bbs2-0110" title="DavisCL . ABC of palliative care. BMJ1997;315(7113):931‐4. ">Davis 1997</a>; <a href="./references#CD007354-bbs2-0112" title="DeConnoF , SpoldiE , CaraceniA , VentafriddaV . Does pharmacological treatment affect the sensation of breathlessness in terminal cancer patients?. Palliative Medicine1991;5:237‐43. ">De Conno 1991</a>; <a href="./references#CD007354-bbs2-0123" title="LankenPN , TerryPB , DelisserHM , FahyBF , Hansen‐FlaschenJ , HeffnerJE , et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Journal of Respiratory and Critical Care Medicine2008;177(8):912‐27. ">Lanken 2008</a>; <a href="./references#CD007354-bbs2-0125" title="ManningHL . Dyspnea treatment. Respiratory Care2000;45(11):1342‐50. ">Manning 2000</a>; <a href="./references#CD007354-bbs2-0132" title="RipamontiC . Management of dyspnea in advanced cancer patients. Supportive Care in Cancer1999;7(4):233‐43. ">Ripamonti 1999</a>; <a href="./references#CD007354-bbs2-0133" title="RockerGM , SinuffT , HortonR , HernandezP . Advanced chronic obstructive pulmonary disease: innovative approaches to palliation. Journal of Palliative Medicine2007;10(3):783‐97. ">Rocker 2007</a>; <a href="./references#CD007354-bbs2-0080" title="RunoJR , ElyEW . Treating dyspnea in a patient with advanced chronic obstructive pulmonary disease. Western Journal of Medicine2001;175(3):197‐201. ">Runo 2001</a>; <a href="./references#CD007354-bbs2-0137" title="ThomasJR , VonGuntenCF . Clinical management of dyspnoea. The Lancet Oncology2002;3(4):223‐8. ">Thomas 2002</a>; <a href="./references#CD007354-bbs2-0138" title="TobinMJ . Dyspnoea. Archives of Internal Medicine1990;150:1604‐13. ">Tobin 1990</a>; <a href="./references#CD007354-bbs2-0139" title="ViolaR , KiteleyC , LloydNS , MackayJA , WilsonJ , WongRK , the Guideline Group. The management of dyspnea in cancer patients: a systematic review. Supportive Care Cancer2008;16(4):329‐37. ">Viola 2008</a>; <a href="./references#CD007354-bbs2-0140" title="WilliamsCM . Dyspnea. Cancer Journal2006;12(5):365‐73. ">Williams 2006</a>). </p> <p>We handsearched the reference lists of the following 16 textbooks: <i>Goodman and Gilman’s The Pharmacological Basis of Therapeutics</i> ; <i>Oxford Textbook of Palliative Medicine</i> ; <i>Textbook of Palliative Medicine</i> ; <i>Textbook of Palliative Nursing</i> ; <i>Palliative Medicine</i> ; <i>Management of Advanced Disease</i> ;<i>Palliative Care Formulary 3</i> ; <i>Oxford Handbook of Palliative Care</i> ; <i>Palliative Medicine ‐ a Case‐Based Manual</i> ; <i>Principles and Practice of Palliative Care and Supportive Oncology</i> ; <i>Dyspnoea in Advanced Disease</i> ; <i>Dyspnoea</i> ; <i>Heart Failure and Palliative Care</i> ; <i>Supportive Care in Respiratory Disease</i> ; <i>Textbook of Respiratory Medicine</i> ; and <i>Palliative Care in Neurology</i>. </p> <p>In addition, we searched seven websites to identify relevant data: <a href="http://www.benzo.org.uk/" target="_blank">www.benzo.org.uk</a>; <a href="http://www.book.palliative.info/" target="_blank">www.book.palliative.info</a>; <a href="http://www.caresearch.com.au/" target="_blank">www.caresearch.com.au</a>; <a href="http://www.cks.library.nhs.uk/" target="_blank">www.cks.library.nhs.uk</a>; <a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com</a>; <a href="http://www.palliativedrugs.com/" target="_blank">www.palliativedrugs.com</a>; and <a href="http://www.patient.co.uk/" target="_blank">www.patient.co.uk</a>. </p> <p>We undertook no further handsearches for this review update.</p> </section> <section id="CD007354-sec-0040"> <h5 class="title">Personal contact</h5> <p>We contacted the following authors of main studies and investigators who are known to be carrying out research in this area for further studies and unpublished data for the original review: Amy Abernethy, Sam Ahmedzai, Eduardo Bruera, Leandro Cerchietti, Jessica Corner, David Currow, Carol Davies, Deborah Dudgeon, Wesley Ely, Tim Harrison, Michio Hosaka, Miriam Johnson, Alfredo Navigante, Andrew Wilcock, and Ashley Woodcock. In addition, we asked all members of the Association of Palliative Medicine (UK) and all users of the bulletin board of <a href="http://www.palliativedrugs.com" target="_blank">www.palliativedrugs.com</a> in a circular letter for additional studies or unpublished data. For the update, we contacted the above mentioned experts again and also asked the following newly identified study investigators for further information on their studies: Scott Bolesta, Eliza S. Daubert, Diana E. Hart, Neil K Hiliard, Fiona Horwood, Clare Randall, and Gerben Stege. </p> </section> <section id="CD007354-sec-0041"> <h5 class="title">Language</h5> <p>There was no language restriction in the selection of studies.</p> </section> </section> </section> <section id="CD007354-sec-0042"> <h3 class="title" id="CD007354-sec-0042">Data collection and analysis</h3> <section id="CD007354-sec-0043"> <h4 class="title">Selection of studies</h4> <p>Two review authors (STS, CB in the original review; VW, STS in the update) independently assessed the relevant titles and abstracts identified. Disagreement was resolved by consensus and with a third review author (IJH in the original review; CB in the update). Three review authors (STS, CB, SB in the original review; VW, STS, CB in the update) independently assessed the full text of all potentially relevant studies, and disagreement at this stage was again resolved by consensus and with a fourth review author (IJH). </p> </section> <section id="CD007354-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (STS, CB, SB) independently extracted data from each appropriate study in the original review; two review authors (STS, VW) did this for the update. We specifically designed an extraction form for collection of relevant data consisting of: </p> <p><b>Study ID and publication details</b>, including: </p> <p> <ul id="CD007354-list-0008"> <li> <p>study aim.</p> </li> </ul> </p> <p><b>Study design and methods</b>, including: </p> <p> <ul id="CD007354-list-0009"> <li> <p>randomisation procedure;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>details of blinding;</p> </li> <li> <p>number and time of follow‐ups;</p> </li> <li> <p>handling of missing data; and</p> </li> <li> <p>details of analysis.</p> </li> </ul> </p> <p><b>Participant characteristics</b>, including: </p> <p> <ul id="CD007354-list-0010"> <li> <p>demographics;</p> </li> <li> <p>diagnosis;</p> </li> <li> <p>performance status;</p> </li> <li> <p>number and description of participants in the intervention and control groups; and</p> </li> <li> <p>setting.</p> </li> </ul> </p> <p><b>Intervention</b>, including: </p> <p> <ul id="CD007354-list-0011"> <li> <p>the drug and its characteristics (e.g. half‐life);</p> </li> <li> <p>route of administration;</p> </li> <li> <p>dose;</p> </li> <li> <p>frequency of application;</p> </li> <li> <p>duration of therapy; and</p> </li> <li> <p>description of placebo.</p> </li> </ul> </p> <p><b>Primary outcomes</b>, including: </p> <p> <ul id="CD007354-list-0012"> <li> <p>measurement of breathlessness; and</p> </li> <li> <p>change in level of breathlessness.</p> </li> </ul> </p> <p><b>Secondary outcomes</b>, including: </p> <p> <ul id="CD007354-list-0013"> <li> <p>adverse effects of benzodiazepines;</p> </li> <li> <p>functional exercise capacity;</p> </li> <li> <p>dose modification;</p> </li> <li> <p>number and reason of withdrawals/attrition;</p> </li> <li> <p>measurement of anxiety;</p> </li> <li> <p>measurement of depression;</p> </li> <li> <p>measurement of quality of life; and</p> </li> <li> <p>arterial blood gas measurements.</p> </li> </ul> </p> <p><b>Additional information</b>, including: </p> <p> <ul id="CD007354-list-0014"> <li> <p>participant comments on intervention.</p> </li> </ul> </p> <p><b>Methodological quality,</b> including: </p> <p> <ul id="CD007354-list-0015"> <li> <p>Risk of bias table (according to Cochrane standard);</p> </li> <li> <p>Edwards Method Score (11 items as described below).</p> </li> </ul> </p> <p>We contacted authors of studies to provide unpublished data for the meta‐analysis where required. </p> </section> <section id="CD007354-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (STS, CB, SB in the original review; STS, VW in the update) independently assessed all selected studies for methodological quality. We used two measures of methodological quality. Firstly, we assessed the quality of studies using the Review Manager (RevMan) 'Risk of bias' table, categorising them as 'low risk', 'high risk', or 'unclear risk' according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007354-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration. Available from www.cochrane‐handbook.org Version 5.1.0 [updated March 2011]. ">Higgins 2011</a>; <a href="./references#CD007354-bbs2-0130" title="The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008. ">RevMan 2008</a>; <a href="./references#CD007354-bbs2-0131" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). Secondly, we graded the quality of studies according to the Edwards Method Score (<a href="./references#CD007354-bbs2-0114" title='EdwardsA , ElwynG , CoveyJ , MatthewsE , PillR . Presenting risk information ‐ a review of the effects of "framing" and other manipulations on patient outcomes. Journal of Health Communication2001;6(1):61‐82. [PUBMED: 11317424] '>Edwards 2001</a>; <a href="./references#CD007354-bbs2-0115" title="EdwardsA , UnigweS , ElwynG , HoodK . Personalised risk communication for informed decision making about entering screening programs. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD001865.pub2] ">Edwards 2003</a>). This checklist of methodological quality contains 11 items that assess the primary research quality of the studies and its published description. The following items were assessed and scored zero, one, or two for adequacy: definition of aims; sample formation; description of inclusion and exclusion criteria; description of participant characteristics; power calculation; objectivity of outcome measures used; adequacy of follow‐up; adequacy of analysis (intention‐to‐treat (ITT)); adjustment for baseline differences between groups; appropriate unit of allocation to groups; and randomisation method. We then constructed a total method score (max 22) and rated the overall quality of the studies as follows: low (12 and under), medium (13 to 14), high (15 and over) (Edwards, personal communication). We integrated the results of the quality assessment in data analysis, as well as in meta‐analysis (cumulative meta‐analysis only in high‐quality studies). </p> </section> <section id="CD007354-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>We used primary and secondary outcomes in the meta‐analysis when appropriate and possible. The primary outcome measures (breathlessness) were either in the form of continuous or ordinal data. We treated all ordinal data as continuous data because the scales used were long enough (following the recommendation of the <i>Cochrane Handbook</i>, <a href="./references#CD007354-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration. Available from www.cochrane‐handbook.org Version 5.1.0 [updated March 2011]. ">Higgins 2011</a>). In the meta‐analysis, we treated studies with cross‐over design in the same way as studies with a parallel design if there was no indication of a carry‐over effect (following the advice of the <i>Cochrane Handbook</i> and after discussion with the statistician of the Cochrane Review Group) (<a href="./references#CD007354-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration. Available from www.cochrane‐handbook.org Version 5.1.0 [updated March 2011]. ">Higgins 2011</a>). We judged the potential existence of a carry‐over effect on a theoretical basis after analysis of the study (for example drug persistency in the body into the next period). We estimated the effect by comparing the post‐treatment measurements of the intervention and the control groups. We calculated the standardised mean differences (SMD) for continuous data with a 95% confidence interval (CI) to show the size of the effect of interventions. Due to the diversity of measurement tools for breathlessness, we used SMD to measure the intervention effect in standardised units. A negative SMD was defined as a beneficial effect of the intervention. We calculated the risk ratio (RR) for dichotomous data to estimate the relative risk. We used risk difference when there was no event in one of the groups (for example for adverse effects or attrition), because the estimation of RR is not possible in this case. For all data we considered a P value of less than 0.05 as statistically significant. </p> </section> <section id="CD007354-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>We combined cross‐over trials and studies with a parallel design in the meta‐analysis and treated the cross‐over studies as parallel design. We did this after a critical analysis of all studies, review of the literature (<a href="./references#CD007354-bbs2-0117" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31:140‐9. ">Elbourne 2002</a>; <a href="./references#CD007354-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration. Available from www.cochrane‐handbook.org Version 5.1.0 [updated March 2011]. ">Higgins 2011</a>), discussion with a statistician, and the following judgements: </p> <p> <ol id="CD007354-list-0016"> <li> <p>the cross‐over design was suitable for the targeted research questions;</p> </li> <li> <p>none of the cross‐over studies showed evidence of a carry‐over effect;</p> </li> <li> <p>dropouts were excluded from analysis;</p> </li> <li> <p>there was no evidence for a period effect. This approach can produce a unit‐of‐analysis error. </p> </li> </ol> </p> </section> <section id="CD007354-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>When means and standard deviations (SD) were missing, we did not impute or estimate them for meta‐analysis, because none of the suggested imputations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> were reliable (after consultation with the statistician of the Cochrane Review Group) (<a href="./references#CD007354-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration. Available from www.cochrane‐handbook.org Version 5.1.0 [updated March 2011]. ">Higgins 2011</a>). We therefore contacted the authors for additional data (means and SD). If they could not provide means or SD, we asked for the original data and calculated means and SD from these data. Data were only retrieved from graphs if exact numbers could be determined. With this procedure, we were able to retrieve all relevant data. </p> </section> <section id="CD007354-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We anticipated clinical heterogeneity because of the differences in diagnostic groups, participants' disease, types of benzodiazepines, doses, duration of treatment, and route of delivery. We measured the impact of statistical heterogeneity (of effects) by quantifying inconsistency using the I<sup>2</sup> statistic and based its interpretation on the recommendations given in the <i>Cochrane Handbook</i> (<a href="./references#CD007354-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration. Available from www.cochrane‐handbook.org Version 5.1.0 [updated March 2011]. ">Higgins 2011</a>). </p> </section> <section id="CD007354-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed selective outcome reporting but did not assess further forms of reporting bias (no further assessment than those included in the 'Risk of bias' tool). </p> </section> <section id="CD007354-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We combined studies using RevMan (Version 5.0 for the original review, Version 5.3 for the update) (<a href="./references#CD007354-bbs2-0130" title="The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008. ">RevMan 2008</a>; <a href="./references#CD007354-bbs2-0131" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We attempted to obtain all relevant data from each paper. </p> <p>We performed a meta‐analysis including all appropriate studies. We excluded studies from the meta‐analysis if the methodological quality of the study was low (Edwards Method Score 12 and lower). We used a random‐effects model because clinical heterogeneity was present. We used the fixed‐effect model only for the presentation of single studies or for studies with adequate homogeneity. </p> </section> <section id="CD007354-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>See section <a href="#CD007354-sec-0049">Assessment of heterogeneity</a>. </p> </section> <section id="CD007354-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook sensitivity analysis to look for influences of different variables (for example participants, interventions, outcomes, and study design). We also performed sensitivity analysis taking into account methodological quality and the robustness of results. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007354-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007354-sec-0054"></div> <section id="CD007354-sec-0055"> <h3 class="title">Description of studies</h3> <p>We have illustrated the study selection process for the update of this review in <a href="#CD007354-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD007354-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007354-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <section id="CD007354-sec-0056"> <h4 class="title">Results of the search</h4> <p>For the update, we included eight studies in total (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>, <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>, <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>, <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>, <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> (updated data which was an unpublished study in the earlier review), <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>, <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a> (this study was awaiting assessment in the earlier review), <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). In addition in this update, we included two study for awaiting classification (<a href="./references#CD007354-bbs2-0100" title="HartDE , CornaNE , HorwoodF , MaingayG . Randomised control trial of intranasal midazolam or oral lorazepam for the relief of dyspnoea in severe respiratory disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2953. ">Hart 2012</a>, <a href="./references#CD007354-bbs2-0099" title="HardyJ , RandallC , PinkertonE , FlatleyC , GibbonsK , AllanS . A randomised, double‐blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life‐limiting disease. Support Care Cancer2016;24:3069. [DOI: 10.1007/s00520‐016‐3125‐2] ">Hardy 2016</a>). </p> <p><b>For the earlier review</b>, we identified a total of 1309 references through the search of 14 databases. We excluded 207 duplicates. We studied the titles and abstracts of each of the 1102 articles and selected relevant articles if they met the inclusion criteria. In the earlier review, we sorted the 1071 excluded articles into the following exclusion groups: different disease (241 articles), different drug (223), reviews (242), anaesthesia‐related study (111), psychology‐related study (61), pharmacokinetic study (45), different design (38), palliative/terminal sedation (37), non‐pharmacological interventions (14), and other (for example children) (59). We retrieved 31 articles for more detailed evaluation in the original review. In the earlier review, we identified 48 additional references from the reference lists of the original 31 articles by handsearching and the auxiliary function ‘Related Articles’ in Science Direct (<a href="http://www.sciencedirect.com" target="_blank">www.sciencedirect.com</a>). The search of 59 reviews, 16 textbooks, and seven websites did not yield any new articles. For the earlier review, we studied a total of 79 articles in more detail after obtaining the full text. Of these 79 articles, seven studies met our inclusion criteria and were included in the earlier review, and one study was awaiting classification (<a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>). We excluded a total of 74 articles for the earlier review. In addition, after sending a letter to all members of the Association of Palliative Medicine (UK) and after personal contact with several investigators (see above) at time of the original review, we were able to identify three new and unpublished studies (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>, <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>, <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>). We received data from two out of the three unpublished studies which we could include in the earlier review (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>, <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>). The author of the third study could not send the data before submission and was set for "awaiting classification" of the earlier review (<a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>). </p> <p><b>For the update of the review</b>, we identified 1884 records: 32 articles in CENTRAL, 92 in MEDLINE, and 1760 in EMBASE. We also identified one potentially relevant clinical study report in trial registries. After de‐duplication, there were 1769 articles for assessment. After screening titles and abstracts and exclusion of 1749 studies (see <a href="#CD007354-fig-0001">Figure 1</a> for reasons of exclusion) we obtained full copies of 19 published studies and one study from trial registries. Of these 20 records, we excluded 17 studies and the record from trial registries (this was a pilot study which failed to recruit any participants and was therefore excluded (<a href="./references#CD007354-bbs2-0067" title="NCT01687751 . Pilot study comparing treatment with dexmedetomidine to midazolam for symptom control in advanced cancer patients. clinicaltrials.gov/show/NCT01687751. ">NCT01687751</a>, personal communication with Neil Hilliard, June 2015)). One of the excluded records was a study protocol only, and the study was cancelled early before any participants were included (<a href="./references#CD007354-bbs2-0026" title="DaubertE , BolestaS . Effect of lorazepam versus morphine on quality of life in hospice patients with dyspnea and anxiety. Journal of the American Pharmacists Association2014, issue 2:e193. ">Daubert 2014</a>; personal communication with Eliza Daubert and Scott Bolesta in June 2015). Two additional studies were considered for awaiting classification. One out of these two studies was published only as a conference abstract and we received no data until the time of submission of the review (see <a href="./references#CD007354-sec-0116" title="">Characteristics of studies awaiting classification</a>) (<a href="./references#CD007354-bbs2-0100" title="HartDE , CornaNE , HorwoodF , MaingayG . Randomised control trial of intranasal midazolam or oral lorazepam for the relief of dyspnoea in severe respiratory disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2953. ">Hart 2012</a>). The second study was published just before the submission of this review and the data will be considered at the next update (conclusion of this study supports the conclusion of the review) (see <a href="./references#CD007354-sec-0116" title="">Characteristics of studies awaiting classification</a>) (<a href="./references#CD007354-bbs2-0099" title="HardyJ , RandallC , PinkertonE , FlatleyC , GibbonsK , AllanS . A randomised, double‐blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life‐limiting disease. Support Care Cancer2016;24:3069. [DOI: 10.1007/s00520‐016‐3125‐2] ">Hardy 2016</a>). Finally for the update, we added one new study to the seven studies of the original review (<a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a> ‐ this study was unpublished and awaited assessment in the earlier review). In addition, we updated data of one previously unpublished but previously included study (<a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>). </p> </section> <section id="CD007354-sec-0057"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD007354-sec-0114" title="">Characteristics of included studies.</a> </p> <p><a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>: a double‐blind, placebo‐controlled, cross‐over RCT tested clorazepate in five non‐anxious participants with severe COPD in a hospital setting to determine whether relieving breathlessness could be achieved. The study started with three arms (7.5 mg/day and 22.5 mg/day oral clorazepate compared to placebo), but the high‐dose arm (22.5 mg) was excluded from analysis after 3 out of 5 participants dropped out due to intolerable adverse effects. The duration of treatment was two weeks with a one‐week wash‐out period. Breathlessness was assessed weekly with a Breathlessness Grade from 1 (little breathlessness) to 6 (extreme breathlessness). Secondary outcomes were anxiety, depression, adverse effects, a 12‐minute walking test, and attrition. </p> <p><a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>: the effectiveness of lorazepam in the relief of breathlessness was tested in a randomised, double‐blind, placebo‐controlled, cross‐over study of 26 participants with advanced cancer in an in‐ and outpatient setting (single‐centre). Seventeen participants completed the study and were included in the analysis. The study tested lorazepam 0.5 mg twice daily orally over five days with a two‐day wash‐out period. A visual analogue scale (VAS) (0 to 100) was used to measure breathlessness as primary outcome (responding to three questions: 1. breathlessness in general over the last 24 hours (summary); 2. breathlessness at its best over the last 24 hours; and 3. breathlessness at its worst over the last 24 hours). Secondary outcomes were anxiety and depression (measured on the Hospital Anxiety and Depression Scale (HADS)) and adverse effects after the treatment. </p> <p><a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>: a double‐blind, placebo‐controlled, cross‐over RCT of 29 participants with advanced but clinically stable COPD in an outpatient setting assessed the efficacy and safety of alprazolam in relieving breathlessness. The analysis included 24 participants, and five participants dropped out. The study compared the effect of alprazolam 1.0 mg/day orally to placebo before and after one week of treatment (with a one‐week wash‐out period after cross‐over). Breathlessness was measured either by Grade of Dyspnoea with 5 (breathlessness at rest) to 2 (able to keep up with people of similar age on level, but not on hills and stairs) to 1 (other than 2 to 5), as well as with a Dyspnoea Scoring (VAS 0 to 10) at rest and during exercise (bicycle ergometer). The study measured adverse effects, attrition, and a 12‐minute walking test as additional outcomes. </p> <p><a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>: a single‐blind RCT with a parallel design assessed the role of midazolam in the alleviation of severe breathlessness during the last week of life of 101 participants with advanced cancer. The investigators conducted a three‐arm trial in a hospital setting comparing morphine only (10 mg/day), midazolam only (20 mg/day), and the combination of morphine plus midazolam (10 plus 20 mg/day), with a treatment duration of 48 hours and subcutaneous administration. The dose was adjusted if the participant was not morphine naive (+25% on top of daily subcutaneous equivalent dose of morphine). Rescue medication was provided with 5 mg midazolam in the morphine group and 2.5 mg morphine in the midazolam and midazolam plus morphine group. Breathlessness was the primary outcome, assessed in four different ways: </p> <p> <ol id="CD007354-list-0017"> <li> <p>Breathlessness intensity with the modified Borg scale (0 to 10) before the intervention and 24 and 48 hours after intervention; </p> </li> <li> <p>Percentage of participants with breathlessness relief (yes/no) after 24 and 48 hours and no breathlessness relief after 48 hours; </p> </li> <li> <p>Numbers of episodes of breathlessness ('breakthrough dyspnoea' = numbers of rescue medication) per participant after 24 and 48 hours; and </p> </li> <li> <p>Percentage of participants with episodic breathlessness after 24 and 48 hours.</p> </li> </ol> </p> <p>Other outcomes were adverse effects (total of clinical relevance and different adverse effects in grading 1 to 3), anxiety, and attrition. </p> <p><a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>: a single‐blind RCT with a parallel design was undertaken with 63 participants with advanced cancer and breathlessness in a single‐centre outpatient clinic (two participants dropped out after randomisation). The aim was to assess the efficacy of oral midazolam for the relief of breathlessness in comparison to oral morphine. A fast titration phase (FTP) was used to determine the effective dose (effect of at least 50% reduction of breathlessness) for the follow‐up phase (FUP) starting with midazolam 2 mg every four hours (excluding sleeping time) and morphine 3 mg every four hours (excluding sleeping time) with incremental steps of 25% of the preceding dose every 30 minutes. The duration of treatment in the FUP was five days with daily assessment of the primary endpoint breathlessness intensity (numeric rating scale (NRS), 0 to 10) and the secondary outcomes number of episodes of breathlessness per day, descriptors the participant used for breathlessness, and the number of adverse effects. The study reported dose reduction, therapeutic failure, and additional procedures (for example antibiotics). </p> <p><a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>: a double‐blind, randomised, placebo‐controlled, cross‐over study of 12 participants with advanced COPD with anxiety (non‐psychiatric stage) in an unknown setting (probably hospital) assessed the effect of alprazolam to relieve breathlessness. Four participants dropped out and were excluded, leaving eight participants for analysis. The study compared the effect of oral alprazolam 0.75 mg/day to placebo at baseline and after two weeks of treatment (with two days wash‐out). Breathlessness was measured on a modified Borg scale (0 to 10). No other outcomes except adverse effects were assessed. </p> <p><a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>: a double‐blind, randomised, placebo‐controlled, cross‐over study of 17 participants with COPD (Global Initiative for Obstructive Lung Disease (GOLD) stages 3 or 4) with insomnia in an outpatient centre of a respiratory medicine hospital department. The aim of the study was to assess whether temazepam (10 mg daily over one week) influences indices of breathing and gas exchanges during sleep; the effect on dyspnoea sensation (assessed with 10‐point VAS) and other outcomes were secondary objectives. Three participants dropped out, leaving 14 participants for analysis. </p> <p><a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>: a double‐blind, placebo‐controlled, cross‐over RCT of 18 participants with severe COPD compared the effect of oral diazepam (25 mg/day) and promethazine (125 mg/day) on breathlessness. Three participants dropped out, leaving 15 participants for analysis. Breathlessness was the main outcome, assessed as 'daily dyspnoea' by VAS (0 to 10) and 'dyspnoea grade' 5 (breathlessness at rest) to 2 (able to keep up with people of similar age on level, but not on hills and stairs) to 1 (other than 2 to 5), after each intervention in an outpatient setting with a two‐week treatment duration (no wash‐out period). The study assessed adverse effects, dose modification, anxiety, depression, a 12‐minute walking test, treadmill, and ergometer measurement. </p> <section id="CD007354-sec-0058"> <h5 class="title">Study design</h5> <p>All studies were RCTs (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). Besides <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a> and <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>, who used a single‐blind, parallel, and morphine‐controlled design, all other studies were double‐blind, cross‐over, and placebo‐controlled (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). </p> </section> <section id="CD007354-sec-0059"> <h5 class="title">Sample size</h5> <p>In general, the sample size was small (between five and 29 participants), except for two studies of Navigante and colleagues (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a> with 101 participants and <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> with 63 participants). One study finished data collection without dropouts (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>). Five studies had between three and nine dropouts (dropout/N: 9/26, 5/29, 4/12, 3/17, 3/18) (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>); one study lost two of 63 participants (<a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>); and one study lost 31 participants due to death during the study (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>), which were always excluded from the analysis. Four studies provided a power calculation (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989;</a><a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>), and three of them reached an appropriate number of participants (<a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>). None of the studies presented an intention‐to‐treat analysis. A total of 214 participants were analysed, including 33 participants of the third intervention arm of the parallel‐designed study from <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>. </p> </section> <section id="CD007354-sec-0060"> <h5 class="title">Participants</h5> <p>Three studies included participants with cancer (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>), and five studies included participants with advanced COPD (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). </p> </section> <section id="CD007354-sec-0061"> <h5 class="title">Outcomes</h5> <p>Breathlessness intensity was measured mainly on a VAS/NRS (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>), a modified Borg scale (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>), and a Dyspnoea Grade 1 to 6 scale or 1 to 5 scale (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). The majority of studies measured breathlessness at rest (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>); only three studies also assessed breathlessness on exercise (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). Two studies assessed episodic breathlessness (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>), and one study did not further specify breathlessness (<a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>). Other outcomes were anxiety (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>), depression (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>), adverse effects (all), walking tests (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>), and attrition (all). </p> </section> <section id="CD007354-sec-0062"> <h5 class="title">Intervention</h5> <p>Two studies tested alprazolam, one with 1.0 mg/day (<a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>), and one with 0.75 mg/day (<a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>). One study tested 25 mg/day diazepam within a three‐arm design with 125 mg/day promethazine compared to placebo (<a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a> applied midazolam 20 mg/day only and in combination with morphine 10 mg/day compared to morphine 10 mg/day only within a three‐arm design. <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> studied oral midazolam 8 mg/day versus morphine 12 mg/day (both starting doses). <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a> examined lorazepam 1 mg/day. <a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a> tested two different doses of clorazepate, 7.5 and 22.5 mg/day, compared to placebo; however, due to intolerable adverse effects, the 22.5 mg arm was excluded from analysis. <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a> examined the effect of temazepam 10 mg/day orally. The treatment durations ranged between 48 hours, in <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>, and two weeks, in <a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>, <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>, and <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>. </p> </section> </section> <section id="CD007354-sec-0063"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD007354-sec-0115" title="">Characteristics of excluded studies</a>. </p> <p>We excluded 90 out of 97 full‐text publications because they did not meet the inclusion criteria (30 'no subjective measurement of breathlessness'; 24 'reviews'; 15 'different drugs'; six 'different disease/healthy participant'; three 'combination of drugs'; six 'different study design', two 'guidelines', two 'editorials', and two studies 'failed in recruiting any participants'. We excluded a substantial number of studies because of a lack of subjective measurement of breathlessness, mainly older studies from the 1970s and 1980s that studied benzodiazepines in relation to spirometry, functional tests, or blood tests. Among them is the most cited paper in this area (<a href="./references#CD007354-bbs2-0060" title="Mitchell‐HeggsP , MurphyK , MintyK , GuzA , PattersonSC , MintyPS , et al. Diazepam in the treatment of dyspnoea in the 'Pink Puffer' syndrome. Quarterly Journal of Medicine1980;49:9‐20. ">Mitchell‐Heggs 1980a</a>), which we had to exclude because of a lack of subjective measurement of breathlessness. Although the authors mentioned breathlessness as an outcome, we could determine no subjective measure, either in the text, tables, or graphs. Other reasons for excluding this study were the lack of systematic or standardised design and absence of control group. Four excluded studies used benzodiazepines only in combination with other drugs (<a href="./references#CD007354-bbs2-0024" title="ClemensKE , KlaschikE . Dyspnoea associated with anxiety ‐ symptomatic therapy with opioids in combination with lorazepam and its effect on ventilation in palliative care patients. Supportive Care in Cancer2011; Vol. 19, issue 12:2027‐33. [1433‐7339] ">Clemens 2011</a>; <a href="./references#CD007354-bbs2-0056" title="LichterfeldA . Controlled therapeutic comparison of antiasthmatics in out‐patients in a double‐blind experiment. Arzneimittel‐Forschung1967;17:1318‐21. ">Lichterfeld 1967</a>; <a href="./references#CD007354-bbs2-0065" title="NaviganteAH , SauriA , PalazzoF , CoppolaM , DeCO , KirchukR , et al. Compared and randomized prospective trial between oxygenotherapy vs. morphine chlorhydrate + midazolam by subcutaneous route in patients with advanced cancer and dyspnea. Prensa Medica Argentina1997;84:474‐6. ">Navigante 1997</a>; <a href="./references#CD007354-bbs2-0066" title="NaviganteAH , CerchiettiLCA , CabalarME . Morphine plus midazolam versus oxygen therapy on severe dyspnea management in the last week of life in hipoxemic advanced cancer patients. Medicina Paliativa2003;10:14‐9. ">Navigante 2003</a>), thus a separate assessment of the drug effect was not possible. Three excluded studies assessed breathlessness in healthy people (comparing diazepam, promethazine, and placebo) (<a href="./references#CD007354-bbs2-0049" title="JonesAL , CameronIR . The effect of promethazine and diazepam on respiratory control in breathless patients (abstract). Clinical Science1985;69:6. ">Jones 1985</a>; <a href="./references#CD007354-bbs2-0085" title="StarkRD , GamblesSA . Does diazepam reduce breathlessness in healthy subjects? (abstract). British Journal of Clinical Pharmacology1982;13:600. ">Stark 1981a</a>; <a href="./references#CD007354-bbs2-0086" title="StarkRD , GamblesSA , LewisJA . Methods to assess breathlessness in healthy subjects: a critical evaluation and application to analyse the acute effects of diazepam and promethazine on breathlessness induced by exercise or by exposure to raised levels of carbon dioxide. Clinical Science1981;61:429‐39. ">Stark 1981b</a>). One study compared diazepam versus flupenthixol in people with psychosomatic disorders (breathlessness was only one of 12 associated symptoms and was not the primary outcome) (<a href="./references#CD007354-bbs2-0047" title="JokinenK . Flupenthixol versus diazepam in the treatment of psychosomatic disorders: a double‐blind, multi‐centre trial in general practice. Pharmatherapeutica1984;3(9):573‐81. ">Jokinen 1984</a>). Although we expected to find a substantial number of observational studies, there were only a few thematically relevant non‐controlled or retrospective studies, which we had to exclude. Among them was the case report from <a href="./references#CD007354-bbs2-0038" title="GreeneJG , PucinoF , CarlsonJD , StorsvedM . Effects of alprazolam on respiratory drive, anxiety, and dyspnea in chronic airflow obstruction: a case study. Pharmacotherapy1989;9:34‐8. ">Greene 1989</a>, a non‐controlled phase II study (<a href="./references#CD007354-bbs2-0009" title="AllcroftP , MargitanovicV , GreeneA , AgarMR , ClarkK , AbernethyAP , et al. The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam. Journal of Palliative Medicine2013;16(7):741‐4. [PUBMED: 23597092] ">Allcroft 2013</a>), the above‐mentioned non‐controlled study on the combined use of opioids and benzodiazepines (<a href="./references#CD007354-bbs2-0024" title="ClemensKE , KlaschikE . Dyspnoea associated with anxiety ‐ symptomatic therapy with opioids in combination with lorazepam and its effect on ventilation in palliative care patients. Supportive Care in Cancer2011; Vol. 19, issue 12:2027‐33. [1433‐7339] ">Clemens 2011</a>), a retrospective study on the management of dyspnoea in hospitalised palliative‐care patients (<a href="./references#CD007354-bbs2-0037" title="GomutbutraP , O'RiordanDL , PantilatSZ . Management of moderate‐to‐severe dyspnea in hospitalized patients receiving palliative care. Journal of Pain and Symptom Management2013; Vol. 45, issue 5:885‐91. [1873‐6513] ">Gomutbutra 2013</a>), and a prospective observational study on the patterns of benzodiazepine use among older adults with COPD in Canada (<a href="./references#CD007354-bbs2-0092" title="VozorisNT , FischerHD , WangX , AndersonGM , BellCM , GershonAS , et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population‐based cohort study. Drugs &amp; Aging2013; Vol. 30, issue 3:183‐92. [1170‐229X] ">Vozoris 2013</a>). We excluded the study <a href="./references#CD007354-bbs2-0044" title="HosakaM , HoshimyamaY . Effects of diazepam on quality of life in patients receiving home oxygen therapy: a double‐blind, cross‐over, placebo‐controlled clinical trial [Japanese]. Journal of the Showa Medical Association1996;5:522‐9. ">Hosaka 1996</a> because four of the 22 participants did not meet our inclusion criteria regarding the underlying disease (asthma, tuberculosis), and the level of airways obstruction was above our inclusion criteria (mean FEV1 63% and FEV1/FVC 1.06), indicating that the disease stage was not as advanced as required for this review. This non‐randomised, placebo‐controlled, double‐blind, cross‐over trial studied the use of diazepam 10 to 12 mg/day over four weeks in 22 people with chronic respiratory insufficiency (mainly COPD and fibrosis) who received home oxygen therapy. The study, which was published in Japanese (abstract in English), showed a statistically significant improvement in breathlessness at rest in the diazepam group and a statistically non‐significant worsening in the placebo group, but the levels of breathlessness at baseline were different between the groups. </p> <p>In the search for the update, we excluded the potentially relevant studies of <a href="./references#CD007354-bbs2-0026" title="DaubertE , BolestaS . Effect of lorazepam versus morphine on quality of life in hospice patients with dyspnea and anxiety. Journal of the American Pharmacists Association2014, issue 2:e193. ">Daubert 2014</a> and <a href="./references#CD007354-bbs2-0067" title="NCT01687751 . Pilot study comparing treatment with dexmedetomidine to midazolam for symptom control in advanced cancer patients. clinicaltrials.gov/show/NCT01687751. ">NCT01687751</a> (identified through register search), because no participants could be recruited in these trials and no future results are expected (personal communication with Neil Hilliard, Eliza Daubert and Scott Bolesta in June 2015). </p> <section id="CD007354-sec-0064"> <h5 class="title">Studies awaiting classification</h5> <p>In the update, we identified one potentially relevant study with the database search (<a href="./references#CD007354-bbs2-0100" title="HartDE , CornaNE , HorwoodF , MaingayG . Randomised control trial of intranasal midazolam or oral lorazepam for the relief of dyspnoea in severe respiratory disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2953. ">Hart 2012</a>), and one potentially relevant study in the clinical trial registries (<a href="./references#CD007354-bbs2-0099" title="HardyJ , RandallC , PinkertonE , FlatleyC , GibbonsK , AllanS . A randomised, double‐blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life‐limiting disease. Support Care Cancer2016;24:3069. [DOI: 10.1007/s00520‐016‐3125‐2] ">Hardy 2016</a>) (see <a href="./references#CD007354-sec-0116" title="">Characteristics of studies awaiting classification</a>). </p> <p><a href="./references#CD007354-bbs2-0099" title="HardyJ , RandallC , PinkertonE , FlatleyC , GibbonsK , AllanS . A randomised, double‐blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life‐limiting disease. Support Care Cancer2016;24:3069. [DOI: 10.1007/s00520‐016‐3125‐2] ">Hardy 2016</a> is a randomised, placebo‐controlled, cross‐over trial testing the hypothesis that intranasal midazolam is superior to placebo for the palliation of dyspnoea in people with optimally treated life‐limiting disease. A sample size of 200 participants was planned but the study was terminated after interim analysis of 75 participants showing no difference between intervention arms. The primary outcome was breathlessness intensity at 15 min compared to baseline. There was no difference at any time points in breathlessness scores between arms. This study concludes that intranasal midazolam had no clinical benefit over intranasal placebo for the control of breathlessness. </p> <p>The aim of the randomised, double‐blind, double‐dummy, placebo‐controlled pilot study of <a href="./references#CD007354-bbs2-0100" title="HartDE , CornaNE , HorwoodF , MaingayG . Randomised control trial of intranasal midazolam or oral lorazepam for the relief of dyspnoea in severe respiratory disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2953. ">Hart 2012</a> was to compare the efficacy of intranasal midazolam with that of oral lorazepam tablets in relieving dyspnoea in people with severe respiratory disease. The study included 30 participants, and the findings showed a "worthwhile improvement in symptom control of dyspnoea and quality of life" (<a href="./references#CD007354-bbs2-0100" title="HartDE , CornaNE , HorwoodF , MaingayG . Randomised control trial of intranasal midazolam or oral lorazepam for the relief of dyspnoea in severe respiratory disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2953. ">Hart 2012</a>). Unfortunately, this study was only published as a conference abstract, and we did not receive data from the authors at time of the submission (personal contact with Dr. Hart in August 2016). </p> </section> </section> </section> <section id="CD007354-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD007354-sec-0114" title="">Characteristics of included studies</a>, the corresponding 'Risk of bias' tables, <a href="#CD007354-fig-0002">Figure 2</a>, and <a href="#CD007354-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD007354-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007354-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <div class="figure" id="CD007354-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007354-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>In the update, seven studies, <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>, <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>, <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>, <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>, <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>, <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>, and <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>, showed high quality on the Edwards Method Score (<a href="./references#CD007354-bbs2-0114" title='EdwardsA , ElwynG , CoveyJ , MatthewsE , PillR . Presenting risk information ‐ a review of the effects of "framing" and other manipulations on patient outcomes. Journal of Health Communication2001;6(1):61‐82. [PUBMED: 11317424] '>Edwards 2001</a>; <a href="./references#CD007354-bbs2-0115" title="EdwardsA , UnigweS , ElwynG , HoodK . Personalised risk communication for informed decision making about entering screening programs. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD001865.pub2] ">Edwards 2003</a>). Only one study had a high risk of bias due to lack of presented data and information and inappropriate presentation of data in figures (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>). We therefore did not include this study in the meta‐analysis. </p> <section id="CD007354-sec-0066"> <h4 class="title">Allocation</h4> <p>All studies were RCTs. Four studies did not mention the denominator population that was screened for participation (<a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). There was a substantial gender imbalance due to more males than females participating in most studies (exact total numbers are not countable because of a different presentation of data for gender of randomised or analysed participants); only <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a> included more females than males. One study did not mention the gender distribution (<a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>). </p> </section> <section id="CD007354-sec-0067"> <h4 class="title">Blinding</h4> <p>Two studies were single‐blinded (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>); one study did not define blinding appropriately, but was stated to be double‐blind (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>); and the rest used a double‐blind design. </p> </section> <section id="CD007354-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>Seven studies with dropouts excluded them from the analysis (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). None of the studies mentioned missing data or the handling of missing data. </p> </section> <section id="CD007354-sec-0069"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a> stated that there was no effect of diazepam in the relief of breathlessness. However, a beneficial effect could be seen for diazepam, although it was not statistically significant (P = 0.06). <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a> stated that no respiratory adverse events had occurred, however there was no information on other than respiratory adverse events. </p> </section> <section id="CD007354-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>Seven studies were published in indexed, peer‐reviewed journals (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a><a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>), and one study was unpublished (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>). The author of the unpublished study sent us all the original data at time of the original review and was very helpful and supportive (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>). One study did not mention a wash‐out period between intervention and control phases (cross‐over design) (<a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). However, sensitivity analysis showed no difference regarding the results compared to studies including a wash‐out period. <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a> used the comparative drug (midazolam plus morphine) for rescue medication. Since this combination of midazolam and morphine could have been used in all three treatment arms, a confident comparison or distinction between midazolam and morphine was not possible. <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> allowed the use of treatments with potential impact on breathlessness besides the intervention and the control in the study (for example antibiotics, aspiration of pleural effusion, radiotherapy). </p> </section> </section> <section id="CD007354-sec-0071"> <h3 class="title" id="CD007354-sec-0071">Effects of interventions</h3> <p>We included eight studies (eight RCTs; six cross‐over and two parallel designs; five COPD and three cancer studies) in the review with a total of 214 participants analysed (COPD, N = 66; cancer, N = 148). We have summarised the main findings of each of the studies below (see also the <a href="./references#CD007354-sec-0114" title="">Characteristics of included studies</a> tables). We carried out the meta‐analysis separately for placebo‐controlled studies, <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>, <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>, <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>, <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>, and <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>, and morphine‐controlled studies (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>). </p> <section id="CD007354-sec-0072"> <h4 class="title">Benzodiazepines for breathlessness in chronic obstructive pulmonary disease (COPD)</h4> <p><a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a> </p> <p>Five participants with advanced COPD were examined in a randomised, cross‐over trial. Breathlessness was measured at rest and after a 12‐minute walking test, after two weeks of treatment with clorazepate 7.5 mg/day compared to placebo. All participants completed the study. The change scores from baseline to postintervention showed no statistically significant difference between the intervention and the control group. The results were presented only in a figure without exact data, which was difficult to interpret. </p> <p><a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a> </p> <p>Twenty‐nine participants with advanced COPD were randomised in a cross‐over design to alprazolam 1.0 mg/day or placebo over one week, but only 24 participants completed the study (five dropouts were excluded from analysis). There was no statistically significant effect of alprazolam versus placebo compared to baseline in the relief of breathlessness at rest and on exercise. Furthermore, no difference between the intervention and the control group was observed after treatment. </p> <p><a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a> </p> <p>Twelve participants with advanced COPD were randomised (cross‐over), of which only eight participants completed the study (four dropouts were excluded from analysis). There was no improvement of breathlessness at rest with alprazolam 0.75 mg/day compared to baseline after two weeks, but there was an improvement with placebo (not statistically significant). Furthermore, no difference was observed after treatment between the intervention and the control group. </p> <p><a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a> </p> <p>Seventeen participants with advanced COPD who experienced insomnia were randomised (cross‐over), of which 14 were analysed, excluding three dropouts. There was no difference of breathlessness intensity with temazepam 10 mg/day for one week compared to placebo. </p> <p><a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a> </p> <p>Eighteen participants with advanced COPD were randomised in a cross‐over design to determine the effect of diazepam 25 mg/day in the relief of breathlessness compared to placebo and promethazine 125 mg/day (third arm). There were three dropouts, and 15 participants completed the study and were included in the analysis. Diazepam produced a statistically non‐significant effect in the relief of breathlessness at rest compared to placebo after two weeks. There was also no difference in breathlessness on exercise compared to placebo. </p> <section id="CD007354-sec-0073"> <h5 class="title">Meta‐analysis and summary</h5> <p>We included four out of five cross‐over studies (see <a href="#CD007354-sec-0065">Risk of bias in included studies</a>) with a total of 61 participants with COPD (122 observations) in the meta‐analysis (<a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>) (<a href="./references#CD007354-fig-0009" title="">Analysis 2.1</a>), comparing post‐treatment measures between intervention and control groups. We observed no statistically significant effect of alprazolam, diazepam, or temazepam with a standardised mean difference (SMD) estimated as ‐0.12 (95% confidence interval (CI) ‐0.52 to 0.29). The overall heterogeneity of effects was low (I<sup>2</sup> = 18%). </p> <p>Overall, the analysis (five studies) and meta‐analysis (four studies) with 66 and 61 participants, respectively, showed no statistically significant effect of four different benzodiazepines (clorazepate, diazepam, alprazolam, temazepam) in the relief of breathlessness in people with advanced COPD. One study showed a slight but statistically non‐significant advantage of diazepam compared to placebo (<a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). </p> </section> </section> <section id="CD007354-sec-0074"> <h4 class="title">Benzodiazepines for breathlessness in cancer</h4> <p><a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a> </p> <p>Twenty‐six participants with advanced cancer were randomised (cross‐over), but only 17 participants completed the study and were included in the analysis. Lorazepam 1.0 mg/day had no statistically significant effect on breathlessness at rest compared to baseline and to placebo after five days of treatment. The result was similar for the overall level of breathlessness, breathlessness at its best, and breathlessness at its worst. </p> <p><a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a> </p> <p>One hundred and one participants with terminal cancer were randomised in a three‐arm study with a parallel design that compared midazolam 20 mg/day, morphine 10 mg/day, and midazolam 20 mg/day plus morphine 10 mg/day after 24 and 48 hours of treatment (plus rescue doses). Thirty‐one participants died during the study after receiving the treatment (no difference between the study groups). Each treatment arm showed a statistically significant reduction of breathlessness compared to baseline, but without any difference when comparing the three arms after 48 hours. After 24 hours, morphine only and the combination of both drugs were slightly better than midazolam only. The highest percentage of participants who experienced a relief of breathlessness (92%) was in the midazolam plus morphine group after 24 hours; the lowest percentage was in the midazolam‐only group (46%). The midazolam group reported the highest percentage of participants with persistent and uncontrolled breathlessness after 48 hours (26%), the midazolam plus morphine group the lowest. </p> <p>For meta‐analysis, we used the assessment after 48 hours unless stated otherwise.</p> <p><a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> </p> <p>Sixty‐three participants with advanced cancer were randomised in a parallel design to compare midazolam 8 mg/day and morphine 12 mg/day (control) over five days (starting doses with titration phase and rescue doses). Sixty‐one participants completed the study, with one drop‐out in each group (31 participants in the midazolam group and 30 participants in the morphine group). Both treatments showed a statistically significant reduction in breathlessness intensity after two, three, four, and five days compared to baseline. Midazolam reduced breathlessness significantly better than morphine when comparing the endpoints after all treatment days. Twenty‐one participants treated with midazolam reached a 50% reduction of breathlessness after the starting dose compared to only 11 participants in the morphine group (P = 0.023). Therapeutic failure was observed in 20% of participants in the morphine group compared to none in the midazolam group. A dose reduction was necessary in one participant in the midazolam group and in two participants in the morphine group due to excessive somnolence. </p> <p>For meta‐analysis, we used the assessment after five days unless stated otherwise.</p> <section id="CD007354-sec-0075"> <h5 class="title">Meta‐analysis and summary</h5> <p>We could include all three studies of people with cancer in the meta‐analysis, but analysed the placebo‐controlled and morphine‐controlled studies separately. The placebo‐controlled study found no statistically significant effect with a SMD of ‐0.06 (95% CI ‐0.73 to 0.62) (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>) (<a href="./references#CD007354-fig-0010" title="">Analysis 2.2</a>). Pooling of the two morphine‐controlled studies also showed no statistically significant effect, with a SMD of ‐0.68 (95% CI ‐2.21 to 0.84) (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>) (<a href="./references#CD007354-fig-0011" title="">Analysis 2.3</a>). One study demonstrated a statistically significant effect of midazolam compared to morphine (<a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>), but this result was contrary to a similar study by the same research group where the morphine group showed a slightly better improvement of breathlessness than the midazolam group (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>). We found no difference when comparing midazolam with midazolam plus morphine (third study arm in <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>). </p> <p>Overall, we found no statistically significant effect. Due to the high level of heterogeneity in the designs of the three studies (control group, study design, stage of disease, benzodiazepine, dose, and route of application), the meta‐analyses of all three studies should be interpreted with caution. There are conflicting results in the comparison of midazolam to morphine based on two studies from the same research group. </p> </section> </section> <section id="CD007354-sec-0076"> <h4 class="title">Benzodiazepines for the prevention of episodic breathlessness in cancer</h4> <p><a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a> </p> <p>The proportion of participants with episodic breathlessness was lower in the midazolam plus morphine group (21.2/24.0%) than in the morphine and midazolam groups after 24 and 48 hours, and highest in the midazolam group (36.4/38.5%). The median number of episodes of breathlessness per participant after 24 and 48 hours was higher in the morphine‐only group (two episodes) than in the midazolam‐only and midazolam plus morphine groups (one episode). </p> <p><a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> </p> <p>The proportion of participants with episodic breathlessness was lower in the midazolam group compared to the morphine group and reached a statistically significant level of P = 0.035 at three days, P = 0.034 at four days, and P &lt; 0.001 at five days of treatment. </p> <section id="CD007354-sec-0077"> <h5 class="title">Meta‐analysis and summary</h5> <p>We could include both studies that examined episodic breathlessness in the meta‐analysis, comparing midazolam with morphine in 116 and 108 participants with cancer, respectively, after 24 and 48 hours (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>). For the second study (<a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>), we calculated the effect after 48 hours using the measurement at the third day when asked about episodic breathlessness on the day before (that is 48 hours). Overall, we found no statistically significant effect after 48 hours with a risk ratio of 0.76 (95% CI 0.53 to 1.09; 108 participants) (<a href="./references#CD007354-fig-0025" title="">Analysis 4.3</a>). </p> <p>Although one study demonstrated a statistically significant positive effect with midazolam after three, four, and five days (<a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>), the previous study from the same research group observed no difference between midazolam and morphine in preventing episodic breathlessness. </p> </section> </section> <section id="CD007354-sec-0078"> <h4 class="title">Overall ‐ benzodiazepines in breathlessness</h4> <section id="CD007354-sec-0079"> <h5 class="title">Meta‐analysis and summary</h5> <p>We excluded one study from the meta‐analysis due to a lack of methodological quality and lack of data (see <a href="#CD007354-sec-0065">Risk of bias in included studies</a>) (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>). Therefore, we included seven studies in the overall meta‐analysis of the review update and analysed placebo‐controlled and morphine‐controlled studies separately. Pooling of the placebo‐controlled studies showed no significant effect with a SMD of ‐0.10 (95% CI ‐0.42 to 0.21) (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>) (<a href="./references#CD007354-fig-0007" title="">Analysis 1.1</a>; <a href="#CD007354-fig-0004">Figure 4</a>). The meta‐analysis of all placebo‐controlled studies included 156 observations equating to 78 participants. Pooling of the morphine‐controlled studies with 107 participants also showed no statistically significant effect with a SMD of ‐0.68 (95% CI ‐2.21 to 0.84) (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>) (<a href="./references#CD007354-fig-0008" title="">Analysis 1.2</a>; <a href="#CD007354-fig-0005">Figure 5</a>). Overall, there was no statistically significant beneficial effect of benzodiazepines in the relief of breathlessness at rest. These results must be interpreted with caution due to the presence of heterogeneity among the seven included studies regarding such components as disease group, control group, and benzodiazepine, among others. </p> <div class="figure" id="CD007354-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Overall, outcome: 1.1 Placebo‐controlled/cross‐over design." data-id="CD007354-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Overall, outcome: 1.1 Placebo‐controlled/cross‐over design.</p> </div> </div> </div> <div class="figure" id="CD007354-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Overall, outcome: 1.2 Morphine‐controlled/parallel design." data-id="CD007354-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Overall, outcome: 1.2 Morphine‐controlled/parallel design.</p> </div> </div> </div> <p>In the sensitivity analysis, a comparison to baseline of studies that presented baseline and after‐treatment measures demonstrated a positive effect for benzodiazepines, but this did not reach statistical significance (data not shown). However, changes from baseline have a higher risk of confounders (for example regression to the mean) compared to after‐treatment measures and should be avoided (<a href="./references#CD007354-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration. Available from www.cochrane‐handbook.org Version 5.1.0 [updated March 2011]. ">Higgins 2011</a>). Two studies looked at breathlessness on exercise (<a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>), but we could not include these in the meta‐analysis due to a lack of appropriate data (data presented only in graphs). </p> <p>In summary, all but one study showed no beneficial effect of benzodiazepines (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>). Only one study showed a statistically significant effect of midazolam compared to morphine (<a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>), but as mentioned above this result was in contrast to a previous study by the same research group (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>). One study demonstrated a beneficial effect of diazepam, but this was not statistically significant (<a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). </p> </section> </section> <section id="CD007354-sec-0080"> <h4 class="title">Secondary outcomes</h4> <section id="CD007354-sec-0081"> <h5 class="title">Anxiety</h5> <p>Four out of seven studies measured anxiety with different scales (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). Benzodiazepines did not reduce anxiety, either as a change from baseline or compared to the control group after treatment. </p> </section> <section id="CD007354-sec-0082"> <h5 class="title">Depression</h5> <p>Three studies examining depression found no statistically significant difference between the intervention and the placebo group (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). </p> </section> <section id="CD007354-sec-0083"> <h5 class="title">Adverse effects</h5> <p>All studies assessed adverse effects, but <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a> only reported on respiratory adverse effects (none occurred). Two studies observed no adverse effects (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>). <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a> described three adverse effects in the intervention group that lead to withdrawal compared to one case in the placebo group. <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a> and <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a> observed significantly more adverse effects (mainly drowsiness) in the benzodiazepine group compared to placebo. <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a> reported more adverse effects (mainly somnolence) in the morphine group (19/45) compared to midazolam (15/45). Surprisingly, the fewest adverse effects were reported for the combination group (11/45; third arm with midazolam plus morphine). The authors defined an adverse effect as clinically relevant with Grade 2 to 4 (Grade 1 mild, 2 moderate, 3 severe, 4 life‐threatening ‐ but observed no Grade 4) and found the highest number in the morphine group (10/16) compared to midazolam (3/16) and midazolam plus morphine (3/16). These results were confirmed in the following study (<a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>), which found significantly more adverse effects (mainly somnolence) in the morphine group compared to the midazolam group. </p> <p>Regarding adverse effects, we observed a beneficial but not statistically significant effect in the control group when studies used placebo as a control (<a href="./references#CD007354-fig-0027" title="">Analysis 5.1</a>, <a href="#CD007354-fig-0006">Figure 6</a>). Studies comparing midazolam with morphine showed a statistically significant favourable effect for midazolam (<a href="./references#CD007354-fig-0028" title="">Analysis 5.2</a>). Drowsiness and somnolence were mainly reported with a statistically significant difference between intervention and control group when placebo was used as a control (benzodiazepines caused more drowsiness or somnolence) (<a href="./references#CD007354-fig-0030" title="">Analysis 5.4</a>). </p> <div class="figure" id="CD007354-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 5 Secondary outcomes, outcome: 5.1 Adverse effects (placebo‐controlled)." data-id="CD007354-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 5 Secondary outcomes, outcome: 5.1 Adverse effects (placebo‐controlled).</p> </div> </div> </div> </section> <section id="CD007354-sec-0084"> <h5 class="title">Exercise tolerance</h5> <p>Only three out of seven studies looked at breathlessness on exercise. <a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a> used a 12‐minute walking distance test and <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a> used a 12‐minute walking distance test and bicycle exercise. They did not find any difference between benzodiazepines and placebo regarding exercise tolerance. However, <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a> demonstrated a significant impairment in walking distance after 12 minutes in the intervention group compared to placebo, and a non‐significant decline in time to exhaustion on treadmill and workload on bicycle ergometer. </p> </section> <section id="CD007354-sec-0085"> <h5 class="title">Quality of life</h5> <p>None of the included studies studied quality of life.</p> </section> <section id="CD007354-sec-0086"> <h5 class="title">Attrition</h5> <p>Regarding attrition, there was no difference between the intervention and control groups, either for the placebo‐controlled studies or the morphine‐controlled studies. Only one study reported results in favour of the intervention group, with four dropouts in the placebo group mainly due to increasing breathlessness and drowsiness (<a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>). One study had no attrition, either in the intervention or in the control group (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>). One study reported three dropouts: one participant was excluded from the intervention group due to an exacerbation of COPD during the study, one participant was excluded due to obstructive sleep apnoea‐hypopnoea syndrome after baseline polysomnography, and one withdrew due to burden of the measurements in the control group (<a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>). One study reported five dropouts (<a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>); one dropout was assigned to the placebo group (unknown adverse effect), and the other four dropouts were missing appointments without assignment to one group. The <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a> study reported twice as many dropouts in the placebo group (six) as in the intervention group (three). Alternatively, <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a> counted twice as many dropouts in the intervention group (two) as in the placebo group (one). The reason for attrition was mainly drowsiness, which occurred in the intervention group in both studies. Both dropouts in <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> were missing follow‐ups. <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a> had a very high attrition rate, and all dropouts were due to death (31 deaths in all three study arms with a total of 101 participants), but without a difference when comparing the three arms. We could find no difference between intervention and control group regarding deaths in all studies (<a href="./references#CD007354-fig-0034" title="">Analysis 5.8</a>; <a href="./references#CD007354-fig-0035" title="">Analysis 5.9</a>). </p> </section> </section> <section id="CD007354-sec-0087"> <h4 class="title">Others</h4> <section id="CD007354-sec-0088"> <h5 class="title">Blood gases</h5> <p>Only one study reported a slightly but almost statistically significant difference (P = 0.05) in blood gases between alprazolam and placebo (PaO<sub>2</sub> at rest higher and PaCO<sub>2</sub> after exercise lower with placebo) (<a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>). All other studies that measured oxygen saturation, PaO<sub>2</sub>, or PaCO<sub>2</sub> found no significant change from baseline or between intervention and control group (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). </p> </section> <section id="CD007354-sec-0089"> <h5 class="title">Spirometric tests</h5> <p>Only one study found a slightly but almost statistically significant difference (P = 0.05) in spirometric tests with higher levels for FEV1 (forced expiratory volume in one second), TLC (total lung capacity), and FRC (functional residual capacity) in the placebo group (<a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>). Three other studies measured the functional lung capacity, but did not find any significant change from baseline or between intervention and control group (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007354-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007354-sec-0090"></div> <section id="CD007354-sec-0091"> <h3 class="title" id="CD007354-sec-0091">Summary of main results</h3> <p>Benzodiazepines are widely used drugs in the treatment of breathlessness, but very few studies have evaluated their effectiveness. On the basis of eight RCTs including 214 participants, we conclude that there is no evidence for a beneficial effect of benzodiazepines for the relief of breathlessness at rest in people with advanced cancer or chronic obstructive pulmonary disease (COPD). However, this conclusion is based on a small number of studies with a limited number of participants, heterogeneity among included studies, and some inconsistency across the studies. Furthermore, we could observe no statistically significant effect in the prevention of episodic breathlessness in people with cancer. Sensitivity analysis demonstrated no statistically significant differences regarding the type of benzodiazepine, dose, route and frequency of delivery, duration of treatment, or type of control. </p> </section> <section id="CD007354-sec-0092"> <h3 class="title" id="CD007354-sec-0092">Overall completeness and applicability of evidence</h3> <p>The study from <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a> is the only RCT that showed a statistically significant beneficial effect, although it used morphine as a control. This result is surprising, as morphine has been shown to be effective in the relief of breathlessness (<a href="./references#CD007354-bbs2-0122" title="JenningsAL , DaviesAN , HigginsJP , BroadleyK . Opioids for the palliation of breathlessness in terminal illness. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD002066] ">Jennings 2001</a>). Furthermore, a study from the same research group of people with terminal cancer two years earlier demonstrated a contrary result, with an advantage of morphine over midazolam, and best results for the combination of the two drugs (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>). However, the results of the earlier study must be interpreted with caution as there were some methodological difficulties: the authors studied people with terminal cancer and observed a very high attrition rate due to death (31/101); and they allowed rescue medication during the study, therefore all three treatment arms might have included both drugs and a valid differentiation of the effect was not possible without uncertainty (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>). Further studies are needed to examine the comparison between morphine and midazolam and to verify the results of <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>. </p> <p>Episodic breathlessness was only studied in people with cancer, and the focus was on preventing breakthrough dyspnoea (no evaluation of the effect on relief of episodic breathlessness) (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>). The extent of the beneficial preventative effect of midazolam compared to morphine was larger after 48 hours than after 24 hours, but statistically non‐significant at both times. RCTs assessing the treatment (not prevention) of episodic breathlessness with benzodiazepines are still missing. </p> <p>Most studies observed adverse effects. Drowsiness and somnolence were mainly reported with a significantly higher occurrence in the benzodiazepine group when a placebo was the control. In contrast to the other studies, <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a> reported attrition only in the placebo group, due to increasing breathlessness and drowsiness. We excluded these three cases from analysis. It could be argued that the occurrence of increasing breathlessness only in the placebo group favours the intervention group in the relief of breathlessness, and this might have changed their conclusion. <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a> argued that this could be a suggestive effect, as participants were told that the treatment might cause increasing breathlessness. However, as only 12 participants were included, it is not possible to judge if this is a random effect. </p> <p>There was no difference between the intervention and control groups in respect to attrition and deaths, either for the placebo‐controlled studies or for the morphine‐controlled studies. However, the reporting of dropouts in cross‐over studies was not always sufficient to assess when the dropout occurred (first or second period of the study), in order to calculate the attrition (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>; <a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>). Given the small numbers of dropouts, the potential miscalculation is likely to be small for the present cross‐over studies. However, attrition must still be interpreted with caution. <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a> observed a high attrition rate due to deaths (31/101) without any difference between the three study arms. As mentioned before, all three treatment arms allowed a combination of midazolam and morphine, therefore the high death rate could not been attributed to a single drug. The authors argued that most of the deaths were caused by the underlying advanced disease. As they studied people with terminal cancer and a life expectancy of less than a week, this seems likely. However, a relation between treatment and death could not be excluded entirely because of the relatively high doses of midazolam. There is some evidence from a large cohort study that benzodiazepines alone might increase mortality, but concurrent benzodiazepines and opioids do not (<a href="./references#CD007354-bbs2-0116" title="EkstromMP , Bornefalk‐HermanssonA , AbernethyAP , CurrowDC . Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ2014;348:g445. ">Ekstrom 2014</a>). </p> <p>Different types of benzodiazepines were tested as well as different doses, long‐ and short‐acting drugs, and different durations of treatment and modes of administration. However, we could find no differences when conducting sensitivity analysis regarding all these criteria. Furthermore, different comparators were used: five studies used placebo (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0003" title="ManGCW , HsuK , SprouleBJ . Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest1986;90:832‐6. ">Man 1986</a>; <a href="./references#CD007354-bbs2-0006" title="ShivaramU , CashM , FinchP . Effects of alprazolam on gas exchange, breathing pattern, and lung function in COPD patients with anxiety. Respiratory Care1989;34:196‐200. ">Shivaram 1989</a>; <a href="./references#CD007354-bbs2-0007" title="StegeG , HeijdraYF , van denElshoutFJ , van deVenMJ , deBruijnPJ , vanSorgeAA , et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respiratory Medicine2010;104(4):518‐24. ">Stege 2010</a>; <a href="./references#CD007354-bbs2-0008" title="WoodcockAA , GrossER , GeddesDM . Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Medical Journal1981;283:343‐6. ">Woodcock 1981</a>), and two studies used morphine as a control treatment (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>). We therefore conducted separate meta‐analyses for each group with the same control treatment. </p> <p>The measurement tools for examining breathlessness in all but one study were validated and frequently used (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>). </p> </section> <section id="CD007354-sec-0093"> <h3 class="title" id="CD007354-sec-0093">Quality of the evidence</h3> <p>Overall, this review analysed 214 participants in eight studies, including 33 participants of the third intervention arm of the parallel‐designed study from <a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>. However, the number of participants in each single study was small (between five and 35 in each comparison group). We intended to evaluate the effect of benzodiazepines in five different disease groups (cancer, COPD, chronic heart failure, motor neurone disease, and idiopathic pulmonary fibrosis), but could only identify studies of people with COPD and cancer. Studies of the other patient groups are also needed. One study identified in the review update included people with different life‐limiting diseases (see <a href="./references#CD007354-bbs2-0099" title="HardyJ , RandallC , PinkertonE , FlatleyC , GibbonsK , AllanS . A randomised, double‐blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life‐limiting disease. Support Care Cancer2016;24:3069. [DOI: 10.1007/s00520‐016‐3125‐2] ">Hardy 2016</a> in <a href="./references#CD007354-sec-0116" title="">Characteristics of studies awaiting classification</a> section). </p> <p>We judged seven out of eight studies to be of high quality on the Edwards Method Score (15 or more on the scale) (<a href="./references#CD007354-bbs2-0115" title="EdwardsA , UnigweS , ElwynG , HoodK . Personalised risk communication for informed decision making about entering screening programs. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD001865.pub2] ">Edwards 2003</a>). To minimise the risk of bias, we excluded one study from the meta‐analysis due to low methodological quality (high risk of bias) based on both the Edwards Method Score and the Cochrane 'Risk of bias' tool (<a href="./references#CD007354-bbs2-0001" title="EimerM , CableT , GalP , RothenbergLA , McCueJD . Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Journal of Family Practice1985;21:359‐62. ">Eimer 1985</a>). However, the single‐blinding process in two studies (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>), and the exclusion of dropouts from analysis, increased the risk of bias in all studies. The 'Risk of bias' tool also revealed that most studies were at unclear risk regarding allocation concealment and potential attrition bias (see "<a href="#CD007354-sec-0065">Risk of bias in included studies</a>") (<a href="#CD007354-fig-0003">Figure 3</a>). The Edwards Method Score has previously been used successfully for judging the quality of non‐pharmacological interventions (for example communication sessions and treatments of breathlessness) (<a href="./references#CD007354-bbs2-0103" title="BauseweinC , BoothS , GyselsM , HigginsonIJ . Non‐pharmacological interventions for breathlessness in advanced stages of malignant and non‐malignant diseases. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005623.pub2] ">Bausewein 2008</a>; <a href="./references#CD007354-bbs2-0115" title="EdwardsA , UnigweS , ElwynG , HoodK . Personalised risk communication for informed decision making about entering screening programs. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD001865.pub2] ">Edwards 2003</a>). Our experience of using the Edwards Method Score to assess the quality of a pharmacological intervention in this review was good, however the tool seems to overestimate the quality of studies compared to the Cochrane 'Risk of bias' tool. </p> </section> <section id="CD007354-sec-0094"> <h3 class="title" id="CD007354-sec-0094">Potential biases in the review process</h3> <p>We combined cross‐over trials and studies with a parallel design in the meta‐analysis and treated the cross‐over studies as parallel design. We did this after a critical analysis of all studies, review of the literature (<a href="./references#CD007354-bbs2-0117" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31:140‐9. ">Elbourne 2002</a>; <a href="./references#CD007354-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration. Available from www.cochrane‐handbook.org Version 5.1.0 [updated March 2011]. ">Higgins 2011</a>), discussion with a statistician, and the following judgements: </p> <p> <ol id="CD007354-list-0018"> <li> <p>the cross‐over design was suitable for the targeted research questions;</p> </li> <li> <p>none of the cross‐over studies showed evidence of a carry‐over effect;</p> </li> <li> <p>dropouts were excluded from analysis;</p> </li> <li> <p>there was no evidence for a period effect. This approach can produce a unit‐of‐analysis error. </p> </li> </ol> </p> <p>However, this error leads to a conservative analysis and under‐weighs the cross‐over studies (<a href="./references#CD007354-bbs2-0120" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration. Available from www.cochrane‐handbook.org Version 5.1.0 [updated March 2011]. ">Higgins 2011</a>). Most cross‐over studies did not show an effect of benzodiazepines in the relief of breathlessness. This conservative analysis therefore supports our conclusion. In addition, sensitivity analysis showed no difference when analysing the cross‐over studies separately (<a href="#CD007354-fig-0004">Figure 4</a>). </p> <p>Two studies presented only median scores for post‐treatment measures because of skewed data (<a href="./references#CD007354-bbs2-0004" title="NaviganteAH , CerchiettiLC , CastroMA , LutteralMA , CabalarME . Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of Pain and Symptom Management2006;31:38‐47. ">Navigante 2006</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>). The mean and standard deviation (SD) was needed to include these studies in the meta‐analysis. Instead of calculating the mean and SD from the median and range, we followed the advice of the statistician of the Cochrane Pain, Palliative and Supportive Care Review Group and obtained the mean and SD from the raw data provided by the author. With this approach we were able to include these studies in the meta‐analysis. </p> <p>Although we used a broad search strategy, we could have missed some unpublished data, such as PhD or Masters theses. However, we identified two unpublished studies through circular mails and personal contact with authors in the original review (<a href="./references#CD007354-bbs2-0002" title="HarrisonTJR . A comparison of the effectiveness of oral lorazepam and placebo in relieving breathlessness associated with advanced cancer. (MSc thesis, 2004). ">Harrison (unpublished)</a>; <a href="./references#CD007354-bbs2-0005" title="NaviganteAH , CastroMA , CerchiettiLC . Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of Pain and Symptom Management2010;39(5):820‐30. ">Navigante 2010</a>) (see Characteristics of ongoing studies). </p> </section> <section id="CD007354-sec-0095"> <h3 class="title" id="CD007354-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p>Three excluded studies assessed breathlessness in healthy participants and could not find a beneficial effect of diazepam (<a href="./references#CD007354-bbs2-0049" title="JonesAL , CameronIR . The effect of promethazine and diazepam on respiratory control in breathless patients (abstract). Clinical Science1985;69:6. ">Jones 1985</a>; <a href="./references#CD007354-bbs2-0085" title="StarkRD , GamblesSA . Does diazepam reduce breathlessness in healthy subjects? (abstract). British Journal of Clinical Pharmacology1982;13:600. ">Stark 1981a</a>; <a href="./references#CD007354-bbs2-0086" title="StarkRD , GamblesSA , LewisJA . Methods to assess breathlessness in healthy subjects: a critical evaluation and application to analyse the acute effects of diazepam and promethazine on breathlessness induced by exercise or by exposure to raised levels of carbon dioxide. Clinical Science1981;61:429‐39. ">Stark 1981b</a>). The trial from <a href="./references#CD007354-bbs2-0044" title="HosakaM , HoshimyamaY . Effects of diazepam on quality of life in patients receiving home oxygen therapy: a double‐blind, cross‐over, placebo‐controlled clinical trial [Japanese]. Journal of the Showa Medical Association1996;5:522‐9. ">Hosaka 1996</a> was the only study excluded because the participants were at non‐advanced disease stage (chronic respiratory insufficiency but lung function tests above our inclusion criteria). This study was also the only non‐RCT study, but with a high risk of bias. A statistically significant improvement in the relief of breathlessness was seen in the intervention group in change from baseline. However, baseline data between intervention and control groups were different. Other methodological problems in this study (no wash‐out phase, breathlessness not primary outcome, sample of participants included a few people with potentially curable disease) necessitate careful interpretation of results. Apart from this trial, we identified no study that looked at people with a non‐advanced disease stage. Furthermore, we included only RCTs in order to reduce the risk of bias, but expected some uncontrolled trials in this area. Surprisingly, we could only find one uncontrolled study (<a href="./references#CD007354-bbs2-0038" title="GreeneJG , PucinoF , CarlsonJD , StorsvedM . Effects of alprazolam on respiratory drive, anxiety, and dyspnea in chronic airflow obstruction: a case study. Pharmacotherapy1989;9:34‐8. ">Greene 1989</a>). This case study reported a beneficial effect of alprazolam in one participant. One excluded study was a single‐site, open‐label pilot study of clonazepam together with sustained‐release morphine with 10 participants who completed the study showed promising results (safety, feasibility) in order to justify a definitive phase III study (<a href="./references#CD007354-bbs2-0009" title="AllcroftP , MargitanovicV , GreeneA , AgarMR , ClarkK , AbernethyAP , et al. The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam. Journal of Palliative Medicine2013;16(7):741‐4. [PUBMED: 23597092] ">Allcroft 2013</a>). </p> <p>After little research activity in this field, with a few studies in the 1980s and no studies during the 1990s, the set‐up of four trials during the last conduction of this review possibly offers hope for further studies, which are urgently needed. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007354-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007354-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007354-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007354-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Overall, outcome: 1.1 Placebo‐controlled/cross‐over design." data-id="CD007354-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Overall, outcome: 1.1 Placebo‐controlled/cross‐over design.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Overall, outcome: 1.2 Morphine‐controlled/parallel design." data-id="CD007354-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Overall, outcome: 1.2 Morphine‐controlled/parallel design.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 5 Secondary outcomes, outcome: 5.1 Adverse effects (placebo‐controlled)." data-id="CD007354-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 5 Secondary outcomes, outcome: 5.1 Adverse effects (placebo‐controlled).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/full#CD007354-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall, Outcome 1 Placebo‐controlled/cross‐over design." data-id="CD007354-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Overall, Outcome 1 Placebo‐controlled/cross‐over design.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Overall, Outcome 2 Morphine‐controlled/parallel design." data-id="CD007354-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Overall, Outcome 2 Morphine‐controlled/parallel design.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disease, Outcome 1 COPD." data-id="CD007354-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Disease, Outcome 1 COPD.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disease, Outcome 2 Cancer ‐ placebo‐controlled." data-id="CD007354-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Disease, Outcome 2 Cancer ‐ placebo‐controlled.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disease, Outcome 3 Cancer ‐ morphine‐controlled." data-id="CD007354-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Disease, Outcome 3 Cancer ‐ morphine‐controlled.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intervention, Outcome 1 Benzodiazepines ‐ alprazolam." data-id="CD007354-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Intervention, Outcome 1 Benzodiazepines ‐ alprazolam.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intervention, Outcome 2 Benzodiazepines ‐ diazepam." data-id="CD007354-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Intervention, Outcome 2 Benzodiazepines ‐ diazepam.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intervention, Outcome 3 Benzodiazepines ‐ midazolam." data-id="CD007354-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Intervention, Outcome 3 Benzodiazepines ‐ midazolam.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intervention, Outcome 4 Benzodiazepines ‐ temazepam." data-id="CD007354-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Intervention, Outcome 4 Benzodiazepines ‐ temazepam.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intervention, Outcome 5 Benzodiazepines ‐ ultra short‐acting." data-id="CD007354-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Intervention, Outcome 5 Benzodiazepines ‐ ultra short‐acting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intervention, Outcome 6 Benzodiazepines ‐ intermediate‐acting." data-id="CD007354-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Intervention, Outcome 6 Benzodiazepines ‐ intermediate‐acting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intervention, Outcome 7 Benzodiazepines ‐ long‐acting." data-id="CD007354-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Intervention, Outcome 7 Benzodiazepines ‐ long‐acting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intervention, Outcome 8 Benzodiazepines ‐ short duration of treatment (≦ 24 hours)." data-id="CD007354-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Intervention, Outcome 8 Benzodiazepines ‐ short duration of treatment (≦ 24 hours). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intervention, Outcome 9 Benzodiazepines ‐ long duration of treatment (5 to 14 days)." data-id="CD007354-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Intervention, Outcome 9 Benzodiazepines ‐ long duration of treatment (5 to 14 days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intervention, Outcome 10 Benzodiazepines ‐ morphine + midazolam‐controlled." data-id="CD007354-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Intervention, Outcome 10 Benzodiazepines ‐ morphine + midazolam‐controlled.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intervention, Outcome 11 Benzodiazepines ‐ promethazine‐controlled." data-id="CD007354-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Intervention, Outcome 11 Benzodiazepines ‐ promethazine‐controlled.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Primary outcome, Outcome 1 Breathlessness ‐ no relief (placebo‐controlled)." data-id="CD007354-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Primary outcome, Outcome 1 Breathlessness ‐ no relief (placebo‐controlled).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Primary outcome, Outcome 2 Breathlessness ‐ no relief (morphine‐controlled)." data-id="CD007354-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Primary outcome, Outcome 2 Breathlessness ‐ no relief (morphine‐controlled).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Primary outcome, Outcome 3 Breathlessness ‐ episodic after 48 hours." data-id="CD007354-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Primary outcome, Outcome 3 Breathlessness ‐ episodic after 48 hours.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Primary outcome, Outcome 4 Breathlessness ‐ episodic after 24 hours." data-id="CD007354-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Primary outcome, Outcome 4 Breathlessness ‐ episodic after 24 hours.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-005-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Secondary outcomes, Outcome 1 Adverse effects (placebo‐controlled)." data-id="CD007354-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Secondary outcomes, Outcome 1 Adverse effects (placebo‐controlled).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Secondary outcomes, Outcome 2 Adverse effects (morphine‐controlled)." data-id="CD007354-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Secondary outcomes, Outcome 2 Adverse effects (morphine‐controlled).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Secondary outcomes, Outcome 3 Adverse effects ‐ clinical relevance only (morphine‐controlled)." data-id="CD007354-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Secondary outcomes, Outcome 3 Adverse effects ‐ clinical relevance only (morphine‐controlled). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Secondary outcomes, Outcome 4 Adverse effects ‐ drowsiness and somnolence only (placebo‐controlled)." data-id="CD007354-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Secondary outcomes, Outcome 4 Adverse effects ‐ drowsiness and somnolence only (placebo‐controlled). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Secondary outcomes, Outcome 5 Adverse effects ‐ drowsiness and somnolence only (morphine‐controlled)." data-id="CD007354-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Secondary outcomes, Outcome 5 Adverse effects ‐ drowsiness and somnolence only (morphine‐controlled). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Secondary outcomes, Outcome 6 Attrition (placebo‐controlled)." data-id="CD007354-fig-0032" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Secondary outcomes, Outcome 6 Attrition (placebo‐controlled).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Secondary outcomes, Outcome 7 Attrition (morphine‐controlled)." data-id="CD007354-fig-0033" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Secondary outcomes, Outcome 7 Attrition (morphine‐controlled).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Secondary outcomes, Outcome 8 Deaths (placebo‐controlled)." data-id="CD007354-fig-0034" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Secondary outcomes, Outcome 8 Deaths (placebo‐controlled).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007354-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/urn:x-wiley:14651858:media:CD007354:CD007354-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_t/tCD007354-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Secondary outcomes, Outcome 9 Deaths (morphine‐controlled)." data-id="CD007354-fig-0035" src="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Secondary outcomes, Outcome 9 Deaths (morphine‐controlled).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/media/CDSR/CD007354/image_n/nCD007354-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD007354-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Placebo‐controlled/cross‐over design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.42, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Morphine‐controlled/parallel design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐2.21, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Overall</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007354-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 COPD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.52, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cancer ‐ placebo‐controlled <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.73, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cancer ‐ morphine‐controlled <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐2.21, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007354-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Benzodiazepines ‐ alprazolam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.41, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Benzodiazepines ‐ diazepam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐1.46, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Benzodiazepines ‐ midazolam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐2.21, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Benzodiazepines ‐ temazepam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐1.91, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Benzodiazepines ‐ ultra short‐acting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐2.21, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Benzodiazepines ‐ intermediate‐acting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.31, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Benzodiazepines ‐ long‐acting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐1.46, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Benzodiazepines ‐ short duration of treatment (≦ 24 hours) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.74, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Benzodiazepines ‐ long duration of treatment (5 to 14 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.42, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Benzodiazepines ‐ morphine + midazolam‐controlled <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.54, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Benzodiazepines ‐ promethazine‐controlled <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.72, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007354-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Primary outcome</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Breathlessness ‐ no relief (placebo‐controlled) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.56, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Breathlessness ‐ no relief (morphine‐controlled) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.91, 3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Breathlessness ‐ episodic after 48 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.53, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Breathlessness ‐ episodic after 24 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.71, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Primary outcome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007354-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Secondary outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse effects (placebo‐controlled) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [‐0.06, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects (morphine‐controlled) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.31, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects ‐ clinical relevance only (morphine‐controlled) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.72, ‐0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects ‐ drowsiness and somnolence only (placebo‐controlled) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.37, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects ‐ drowsiness and somnolence only (morphine‐controlled) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.30, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Attrition (placebo‐controlled) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.23, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Attrition (morphine‐controlled) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.08, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Deaths (placebo‐controlled) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.06, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Deaths (morphine‐controlled) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.06, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Secondary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007354.pub3/references#CD007354-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007354.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007354-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007354-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD007354-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007354-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007354\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007354\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007354\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007354\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007354\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007354.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007354.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007354.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007354.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007354.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725253155"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007354.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725253159"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007354.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e76b81acb936e',t:'MTc0MDcyNTI1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 